AN ACTIVATION DEVICE TRAP GAS EVACUATED GLASS

HEAD OF A TRIMMER

ROTARY DEVICE WITH TRIPOD

L'invention concerne un dispositif rotatif à monopode, comprenant une tige principale (1), une plate-forme d'adaptation (2) destinée à fixer un équipement photographique, et un dispositif rotatif connectant avec possibilité de rotation la plate-forme d'adaptation (2) à la tige principale (1), caractérisé en ce que ledit dispositif rotatif comprend un tube rotatif (3), emboîté autour de ladite tige principale (1), une première structure de connexion, connectant de manière fixe ladite plate-forme d'adaptation (2) à une extrémité supérieure dudit tube rotatif (3), une deuxième structure de connexion, connectée de manière fixe à une extrémité supérieure de ladite tige principale (1), et une structure de connexion de rotation, disposée entre ladite première structure de connexion et ladite deuxième structure de connexion, de sorte que ladite première structure de connexion et ladite deuxième structure de connexion soient connectées l'une à l'autre avec possibilité de rotation relative.

PROCESS OF DIRECTIONAL ELECTROMAGNETIC RESISTIVITY

NEW DERIVATIVES OF BENZOTHIOPHENE, PRESENTING AN INHIBITING ACTIVITY OF THE TNAP

PROCESS AND DEVICE Of INSPECTION OF LIQUID PRODUCTS

Sont décrits un procédé et un dispositif d'inspection de sécurité de produits liquides avec imagerie par tomodensitométrie double énergie. Le procédé comprend les étapes consistant à obtenir une ou plusieurs images de tomodensitométrie incluant des attributs physiques du produit liquide à inspecter par balayage par tomodensitométrie et un procédé de reconstruction double énergie ; acquérir les attributs physiques de chaque produit liquide à partir de l'image de tomodensitométrie ; et déterminer si le produit liquide inspecté est dangereux en se basant sur les attributs physiques. Le balayage par tomodensitométrie peut être mis en oeuvre par une technique de balayage par tomodensitométrie normale, ou une technique de balayage par tomodensitométrie en spirale. Dans la technique de balayage par tomodensitométrie normale, on peut fixer à l'avance la position de balayage ou elle peut être déterminée par l'opérateur avec une image de radiographie numérique ou déterminée par une analyse automatique ...

MEMBRANES OF PVDF HAS SURFACE SUPERHYDROPHOBE

La présente invention se rapporte au domaine des surfaces solides hydrophobes, et plus particulièrement aux membranes de polyfluorure de vinylidène (PVDF) à surface superhydrophobe. L'invention concerne également le procédé de préparation de ces membranes ainsi que leurs applications industrielles. Les membranes de PVDF selon l'invention comprennent une surface superhydrophobe comprenant une structure rugueuse à l'échelle nanométrique et des nodules cristallins interconnectés.

ROTOR OF REVOLVING ELECTRIC MACHINE AND REVOLVING ELECTRIC MACHINE INCLUDING/UNDERSTANDING SUCH A ROTOR

Le rotor (1) selon l'invention comprend une pluralité de pôles Nord (N) et pôles Sud (S) alternés et formés à partir d'une pluralité d'aimants permanents (3) agencés dans des premiers évidements (4). Ces premiers évidements sont répartis régulièrement autour d'un axe (5) du rotor et se prolongent axialement dans une masse magnétique (2) de celui-ci de manière à définir un nombre prédéterminé de sections polaires (9) circonférentielles. Ces sections polaires comportent des deuxièmes évidements (12) agencés entre les aimants permanents et se prolongent axialement dans la masse magnétique de manière à définir une pluralité de ponts magnétiques (14, 15) présentant une pluralité de hauteurs (htri) dans une partie circonférentielle (11) du rotor. Conformément à l'invention, une première hauteur (htr1) et une deuxième hauteur (htr2) de deux dits ponts magnétiques (14, 15) consécutifs sont différentes.

APPLICATION OF CUSTOMER SERVICE FOR A PORTABLE ELECTRONIC DEVICE

Une application Service Client résidant sur un dispositif électronique portable d'un utilisateur set à obtenir des informations concernant un service offert par un magasin et à demander le service. Cette application peut vérifier les magasins à proximité lors de son démarrage . Une fois que l'utilisateur est considéré comme se trouvant dans la zone de service du magasin (502), le serveur informatique hôte du magasin peut commencer à envoyer des informations concernant différents produits , services, événements ou ateliers proposés par le magasin (510). L'utilisateur peut utiliser l'application pour demander de l'aide sur un produit ou un service auprès d'employés du magasin, pour s'enregistrer à un événement/atelier, pour réserver un produit à retirer , etc.

FILM-FORMING COMPOSITIONS COMPRISING SYNTHETIC LAYERED SILICATE

Massage chair for use in office, has electric current adapter and manual controller installed on base, where inner massage device is connected to current adapter and controller and is fixed on inner frame of backrest by self-tapping screw

La demande concerne un siège de massage comprenant un dossier (1), une assise (6) avec un revêtement souple et un dispositif de réglage de hauteur en-dessous de l'assise (6). La partie inférieure du dispositif de réglage de hauteur est connectée à un piétement (11) avec des roulettes (14). Le dossier (1) est équipé d'un cadre intérieur sur lequel est fixé un dispositif de massage intérieur (3), et un adaptateur de courant électrique (12) et un contrôleur manuel (2) sont installés sur l'assise (6), le dispositif de massage interne (3) étant relié à l'adaptateur de courant (12) et le contrôleur manuel (2).

Doll-shaped charger for charging rechargeable battery for power supply of e.g. smartphone for outdoor use, has conducting part including terminal connected to negative pole, and another terminal mounted on seat and corresponding to chamber

La présente invention fournit un chargeur en forme de poupée compact et portable avec une apparence amusante, en particulier pour une utilisation en extérieur. Il a les caractéristiques suivantes ; une conformation d'apparence intéressante et spécifique, un corps de poupée (1) comprenant un espace de réception principal (10) et un espace de réception secondaire (20), une prise de recharge (2) située dans l'espace de réception principal (10) et à travers la surface du corps de poupée (1) pour le branchement d'une ligne d'alimentation d'un dispositif électronique portable, un boîtier (3) de batteries modulaire situé dans l'espace secondaire de réception (20) et reliée électriquement à la prise de recharge (2) et une carte à circuit imprimé (4), électriquement connectée à la prise de recharge (2) et apte à délivrer la puissance électrique de la batterie à un dispositif électronique portable.

PROCESS AND DEVICE OF MEASUREMENT Of an INTERFACIAL OR SURFACE TENSION BY PENETROMETRIE Of an INTERFACE BETWEEN TWO FLUIDS.

Electrical energy storage system i.e. battery, characterization device, has power channel, and commutation unit connected to storage system to impose exchange of current entering device and storage system connected to channel

Dispositif de caractérisation (10, 20) de systèmes de stockage d'énergie électrique (B1, Bn), agencé pour être connecté simultanément aux systèmes de stockage d'énergie électrique (B1, Bn), pour effectuer la mesure d'au moins une caractéristique pendant un échange de courant électrique, caractérisé en ce que le dispositif de caractérisation (10, 20) comprend : - une seule voie de puissance agencée pour échanger du courant électrique avec les systèmes de stockage d'énergie électrique (B1, Bn), et - des moyens de commutation (41, 4n) agencés pour connecter un des systèmes de stockage d'énergie électrique (B1, Bn) à la voie de puissance tout en en déconnectant les autres systèmes de stockage d'énergie électrique (B1, Bn).

APPARATUS FOR ASEPTICALLY FILLING FOR A FACE MASK AND PREPARATION METHOD FOR FACIAL MASK

La présente description appartient au domaine technique des cosmétiques, concerne plus spécifiquement un appareil de remplissage aseptique (stérile) pour un masque facial et un procédé de préparation de masque facial. L'appareil de remplissage aseptique pour un masque facial comprend une enceinte de séchage à haute température, une cuve de stérilisation à haute pression et à haute température (1), un tube de distribution (2) capable d'être stérilisé à la vapeur à haute température, une machine de remplissage (3) capable d'être stérilisée à la vapeur à haute température, et un atelier de remplissage ayant une propreté de classe cent. Cet appareil peut parfaitement stériliser les masques faciaux, c'est-à-dire garantir que les masques faciaux sont aseptiques sans ajout de conservateurs aux masques faciaux.

SCREEN LED REDUCED SPACING

Un écran à DEL à espacement réduit, comprenant un boîtier de fond (1), un panneau concentrateur (HUB) (2) agencé d'un côté du boîtier de fond (1) et des petits modules agencés de l'autre côté qui sont reliés électriquement au panneau concentrateur (2), est fourni. Le petit module comprend un corps principal de module et une unité de commande de pilotage qui est reliée de manière électrique au corps principal du module pour piloter et commander le corps principal du module. Une plaque adaptatrice (4) est également agencée entre le petit module et le panneau concentrateur (2). Le panneau concentrateur (2) est relié électriquement à la plaque adaptatrice (4). L'unité de commande de pilotage est agencée sur la plaque adaptatrice (4). L'écran à DEL possède l'espacement le plus petit possible et le taux de rejet du petit module est considérablement réduit.

DETECTING ENGINE HAS DOUBLE NETWORK FOR IMAGERY BY RADIATION

La présente invention propose un module détecteur à double réseau adapté à l'imagerie par rayonnement, comprenant un premier réseau de détecteurs (1a) consistant en une pluralité de premiers détecteurs et agencé sur une première surface d'une plaque métallique lourde (5), un deuxième réseau de détecteurs (1b) consistant en une pluralité de deuxièmes détecteurs et agencé sur une deuxième surface de la plaque métallique lourde, la deuxième surface étant opposée à la première surface, et un cadre support, dans lequel le premier réseau de détecteurs et le deuxième réseau de détecteurs agencés respectivement sur les première et deuxième surfaces de la plaque métallique lourde sont montés dans le cadre support. Ce module détecteur à double réseau est de structure simple, et est pratique à assembler et à entretenir, ce qui permet un grand bénéfice économique.

CONNECTION ELEMENT, THE CONNECTION ASSEMBLY, MODULE SUPPORT ASSEMBLY OF BATTERY AND BATTERY MODULE

AUTOMATIC POWER PLANT INTEGRATED IN A SOUND-PROOF BOX TIGHT SAND

PUMP CONTROL ELEMENT

L'invention porte sur une pompe (1) comprenant un élément de régulation de pression d'un fluide la traversant, une pression du fluide en sortie de la pompe (1) étant régulée par une action de l'élément de régulation, l'élément de régulation comprenant deux ressorts (2, 2a) dont un ressort intérieur (2a) entouré par un ressort extérieur (2), telle que l'élément de régulation comprend un bloc de support commun pour les deux ressorts (2, 2a) comprenant deux échelons de différentes hauteurs, chaque échelon supportant un ressort (2, 2a) respectif.

VERFAHREN ZUR ÜBERTRAGUNG VON INFORMATIONEN IN EINEM KOMMUNIKATIONSSYSTEM UNTER VERWENDUNG EINES PFADES

APPARATUS FOR THE COLLECTION AND TREATMENT OF GREY WATER AND WASHING METHOD

LIQUID CRYSTAL DISPLAY PANEL

SYSTEM OF TREATMENT OF WOUND BY PRESSURE NEGATIVE AND PROCEEDED OF ORDER HAS FEEDBACK FOR THIS ONE

L'invention porte sur un système de traitement de plaie par pression négative qui crée un environnement de pression négative dans l'ouverture (511) d'une unité pansement (50) et un environnement de pression positive dans le sac de collecte. Ensuite, une procédure de détection de pression positive est conduite dans l'environnement de pression positive et une procédure de détection de pression négative est conduite dans l'environnement de pression négative. Les résultats de détection sont envoyés pour déterminer si une micro-pompe (31) doit être arrêtée. A negative pressure wound treatment system creates a negative pressure environment in the opening (511) of a dressing unit (50) and a positive pressure environment in the collection bag. Next, a positive pressure detection procedure is conducted in the positive pressure environment and a negative pressure detection procedure is conducted in the negative pressure environment. The detection results are sent to determine if a micro-pump (31) should be stopped.

SYNCHRONOUS REVOLVING ELECTRIC MACHINE WITH ROTOR HAS DOUBLE EXCITATION

HYDRAULIC DAMPER

METHOD FOR CONTROLLING A SYNCHRONOUS ROTARY ELECTRICAL MACHINE WITH DOUBLE EXCITATION AND CORRESPONDING ROTARY ELECTRIC MACHINE

HAMMER ELECTRIC MULTIFUNCTION SWITCHABLE BETWEEN DIFFERENT OPERATION MODES

Ce marteau présente un boîtier, un cylindre tournant (10), un marteau percuteur incorporé dans le cylindre (10), un module de percussion, un module de rotation pour l'entraînement du cylindre tournant (10), un moteur électrique (1), une roue dentée (18) pour la sortie d'énergie, la roue dentée (18) étant engrenée simultanément avec deux groupes de roues dentées d'entraînement (4) montés séparés l'un de l'autre et étant couplés respectivement avec le module de percussion ou le module de rotation. Un dispositif de couplage est disposé entre le module de percussion, le module de rotation et les roues dentées d'entraînement (4), un mécanisme de commutation (2) étant monté sur le marteau électrique, et un ressort de rappel étant disposé entre le module de percussion et le module de rotation.

Connection structure for connecting batteries used in e.g. portable radio apparatus, has hook ring forming part allowing fixation of end of conducting part between round lid and negative electrode by being in contact with negative electrode

Cette structure est caractérisée en ce qu'elle comprend les caractéristiques suivantes : un corps (1), comprenant un couvercle arrondi (11) auquel sont fixées des parois de support (12) ; un fond (2) destiné à être fixé à l'autre extrémité des parois de support (12) de manière à définir un premier, un deuxième et un troisième espaces de réception de piles (10, 20, 30) ; une anode (3) et une électrode négative (4), disposées sur le couvercle arrondi (11) ; des pièces conductrices reliant les espaces de réception (10, 20, 30).

PROCEEDED Of INSPECTION OF SAFETY OF LOADING BASES ON a SWEEPING IN SPIRAL.

Static interrupting device.

PROCESS Of ADMINISTRATION Of an OPEN COMPUTING SYSTEM

AUXILIARY MANUAL BRAKE SYSTEM OF VEHICLE

CHEMICO-MECANICAL COMPOSITION OF POLISHING, EXEMPTS CELLULOSE WATER-SOLUBLE, CONCENTRABLE, STABLE

Une composition de polissage chimico-mécanique utile pour polissage chimico-mécanique d'une plaquette de semiconducteurs contenant un métal d'interconnexion, est fournie, comprenant, en tant que composants initiaux : de l'eau ; un inhibiteur de type azole ; un agent tensio-actif organique de métal alcalin ; un hydrotrope ; un agent contenant du phosphore ; éventuellement, un polymère non saccharidique hydrosoluble ; éventuellement, un composé acide hydrosoluble de formule I ; éventuellement, un agent complexant ; éventuellement, un agent oxydant ; éventuellement, un solvant organique ; éventuellement, un abrasif. Par ailleurs il est également fourni un procédé de fabrication d'une composition de la présente invention et un procédé de polissage chimico-mécanique d'un substrat, comprenant : la fourniture d'un substrat, le substrat étant une plaquette de semi-conducteurs avec interconnexions en cuivre ; la fourniture d'une composition selon la présente invention ; la fourniture d'un tampon ...

VEHICLE COMPRISING A DEFLECTING DEVICE AND DEFLECTOR DEVICE

L'invention concerne un véhicule (10), comprenant des supports longitudinaux avant (11) s'étendant vers l'avant à partir d'un habitacle de conduite (12), qui délimitent en partie un compartiment moteur (13) dans lequel est positionné un groupe motopropulseur (14), et comprenant un dispositif déflecteur (17) présentant des éléments déflecteurs (18) fixés de manière à pouvoir tourner autour d'un axe de rotation vertical (24) au niveau des supports longitudinaux avant (11), un élément déflecteur (18) pouvant être tourné en cas de collision frontale depuis une position de repos dans une position de collision par rapport au support longitudinal avant respectif (11), de telle sorte qu'une première portion (19) de l'élément déflecteur (18) pénètre dans le compartiment moteur (13) et convertisse une impulsion longitudinale de la collision frontale, au moins en partie en une impulsion transversale.

AC-DC CONVERTER

Convertisseur alternatif - continu (100) destiné à être intégré dans une machine électrique tournante, comprenant : - au moins un module de puissance (12), - un module de contrôle permettant de contrôler le au moins un module de puissance (12), - un dispositif de refroidissement (14), dans lequel le au moins un module de puissance (12) est fixé au dispositif de refroidissement (14) par l'intermédiaire d'au moins un moyen de fixation (23), et le module de contrôle repose sur le au moins un moyen de fixation (23) de sorte à transférer la chaleur générée par au moins une partie du module de contrôle vers le dispositif de refroidissement (14).

METHOD FOR RECONSTRUCTING IMAGE FOR COMPUTERIZED TOMOGRAPHIC IMAGING SYSTEM OF DUAL ENERGY HIGH ENERGY

Un procédé de reconstruction d'image dans un système de CT de double énergie à haute énergie est décrit. Le procédé comprend les étapes consistant à balayer (S11) un objet avec des rayons de double énergie à haute énergie pour obtenir des valeurs de projection de double énergie à haute énergie, calculer (S 12) les valeurs de projection des coefficients du matériau de base correspondant aux valeurs de projection à double énergie en se basant sur un tableau de correspondance créé à l'avance ou en résolvant de façon analytique un système d'équations, et obtenir (S13) une image de la distribution des coefficients du matériau de base en se basant sur les valeurs de projection des coefficients du matériau de base. Le procédé fournit une solution pour la reconstruction avec une technologie de CT de double énergie à haute énergie et ainsi, une approche plus efficace d'identification de substances et de contrôle de contrebande, en apportant ainsi une amélioration significative à la précision et ...

IMAGING WITH SHIELD FOR MOTOR VEHICLE

On propose un dispositif d'imagerie (300) pour véhicule automobile. Le dispositif d'imagerie comprend un écran (110) à transmission ou réflexion variable dans une pluralité de zones pilotables sélectivement, l'écran étant configuré pour la formation d'une image, une source lumineuse (130-136) cohérente apte à éclairer ledit écran, et un vibreur électromécanique (316-318) configuré pour mettre en vibration au moins une partie de la source lumineuse. Cela offre un dispositif d'imagerie pour véhicule automobile amélioré.

HYDRAULIC SHOCK ABSORBER

L'invention divulgue un amortisseur hydraulique comprenant un rotor (1), un stator (2) et un arbre d'entraînement (3) pour entraîner le rotor (1), le rotor (1) et le stator (2) formant mutuellement une chambre de travail (4) dans laquelle un milieu liquide est contenu, dans lequel le stator (2) est pourvu à son tour d'une sortie (21), d'une buse (22), d'un canal d'échappement (23), d'un canal éjecteur (24) et d'une entrée (25) ; la sortie (21), le canal d'échappement (23) et l'entrée (25) sont mis en communication avec la chambre de travail (4), respectivement ; le canal éjecteur (24) est en communication avec la sortie (21), le canal d'échappement (23) et l'entrée (25), respectivement ; la buse (22) est agencée à la jonction où la sortie (21) est connectée au canal d'échappement (23) et au canal éjecteur (24) ; la buse (22) est étendue le long de la direction de sortie de la sortie (21) à la jonction où le canal d'échappement (23) est connecté au canal éjecteur (24) et la largeur de canal ...

Door e.g. front door, closure authorization determining method for e.g. bus, involves comparing outer environmental states of door, and preventing closing of door when environmental states are different

Un dispositif avec une fonction de mémoire pour déterminer si ou non une porte de véhicule est autorisée à se fermer et son procédé sont décrits. Avant qu'une porte de véhicule ne soit ouverte, un signal de détection près du côté extérieur de la porte est émis et son état de détection est enregistré. Lorsque la porte de véhicule doit être fermée, un premier signal de détection est émis à partir de la partie supérieure du cadre de porte vers le bas et un second signal de détection est émis près du côté extérieur de la porte. Si le premier signal de détection indique qu'une personne est au niveau de la porte ou que le second signal de détection indique qu'une personne est présente sur le côté extérieur de la porte par comparaison avec un enregistrement précédent, alors on empêche la porte de se fermer. Sinon, la porte peut être fermée.

DEVICE HAS PART OF CHANGE-OVER CONTACT FOR the INTERRUPTION OF the CURRENT LIKE DISCONNECTING SWITCH USING the DEVICE

Dispositif à pièce de contact double pour l'interruption du courant, qui comporte un corps ( 12 ), une partie ( 11 ) d'entraînement une première pièce ( 21 ) de contact statique, une deuxième pièce ( 31 ) de contact statique, une première pièce ( 22 ) de contact mobile, une deuxième pièce ( 32 ) de contact mobile, la partie ( 11 ) d'entraînement est reliée au corps ( 12 ) au moyen d'un axe ( 17 ), tandis que la première pièce ( 21 ) de contact statique et la deuxième pièce ( 31 ) de contact statique, la première pièce ( 22 ) de contact mobile et la deuxième pièce ( 32 ) de contact mobile, sont disposés symétriquement par rapport à l'axe ( 17 ) principal.

EMPENNAGE ABLE TO IMPROVE the PERFORMANCES the ANTI-COLLISION one WITH a BIRD Of a PLANE

Selon la présente invention, un renfort de bord d'attaque (6) ayant une forme de triangle isocèle est situé à l'intérieur d'un bord d'attaque d'empennage. Le renfort de bord d'attaque (6) est fixé dans le sens de l'envergure dans des sections entre des étendues respectives formées par la nervure d'aile (8). Les degrés de l'angle au sommet du renfort de bord d'attaque (6) sont les mêmes que les degrés de l'angle au sommet du revêtement de bord d'attaque d'empennage (5). Le renfort de bord d'attaque (6) est relié de façon fixe au petit longeron avant (7) par une surface de fixation de renfort de bord d'attaque (11). Lorsque l'aile est frappée par un oiseau, le revêtement de bord d'attaque se colle sur la structure de support en triangle afin de segmenter l'énergie de l'oiseau de façon à protéger le longeron avant d'empennage contre une rupture.

PHOSPHOR OXICARBONITRIDE HALOGEN AND DEVICES USING SAME

La présente invention concerne un luminophore rouge, comprenant : un composé inorganique représenté par la formule (1) M(I)eM(II)fM(III)gSijNuCxOwHv:zA (1) où M(I) est au moins un cation monovalent ; où M(II) est au moins un cation divalent ; où M(III) est au moins un cation trivalent ; où H est au moins un anion monovalent d'halogène; où A est au moins un activateur de luminescence ; où 0 < e ≤ 0,5 ; où 0,5 ≤ f≤ 1 ; où 0,5 ≤ g ≤ 1 ; où 1 ≤ j < 1,5 ; où 0 < u < 3 ; où 0 < x ≤ 2 ; où 0 < w≤ 0,75 ; où 0 < v < 1 ; où 0 < (x+w) < 3 ; où x≠w; et, où 0 < z≤ 0,5. La présente invention concerne en outre un appareil d'éclairage contenant un luminophore rouge.

GRILL DEVICE

SENSOR Of INFRA-RED AND PROCEEDED IMAGEUR Of VACUUM PACKAGING.

Un capteur d'image infrarouge et un procédé d'encapsulage sous vide sont présentés. Le capteur d'image infrarouge comprend un support en céramique (210), un couvercle en métal (220) et un filtre infrarouge (230). Le support en céramique (210) a une plaque de capture d'image infrarouge (240) fixée dessus et le couvercle en métal (220) comprend un dégazeur (221) déposé sur une face intérieure du couvercle en métal (220). Le filtre d'infrarouge (230) scelle une ouverture du couvercle en métal (220). Le support en céramique (210), le couvercle en métal (220) et le filtre infrarouge (230) sont chauffés dans une chambre à vide pour activer le dégazeur (221) et souder ensemble le support en céramique (210), le couvercle en métal (220) et le filtre infrarouge (230), encapsulant ainsi sous vide le capteur d'image infrarouge.

DEVICE HAS EMISSION OF FIELD

En modelant une couche de catalyseur à une échelle micrométrique et en construisant des nanotubes (103) sur celle-ci, la zone d'émission est constituée de nombreux petits îlots d'émission. Chaque îlot d'émission comporte des nanotubes finis (103) à densité nominale. Du fait du très grand nombre d'espaces entre les îlots d'émission, relativement plus de nanotubes (103) sont exposés à la région du bord de l'émetteur, ce qui accroît efficacement l'espacement mutuel moyen des nanotubes (103). L'effet d'arrêt de champs est ainsi très réduit.

COMPOSITION OF POLISHING CHEMICO-MECANICAL, CONCENTRABLE, STABLE AND PROCEEDED BEING ATTACHED TO it

Une composition de polissage chimico-mécanique utile pour polissage d'une plaquette de semi -conducteurs contenant un métal d'interconnexion, est fournie, comprenant, en tant que composants initiaux : de l'eau ; un inhibiteur de type azole ; un agent tensio-actif organique de métal alcalin ; un hydrotrope ; un agent contenant du phosphore ; une cellulose hydrosoluble ; éventuellement, un polymère non saccharidique hydrosoluble ; éventuellement, un composé acide hydrosoluble de formule I, éventuellement, un agent complexant; éventuellement, un agent oxydant ; éventuellement, un solvant organique ; éventuellement, un abrasif. Par ailleurs est également fourni un procédé de préparation d'une composition de la présente invention et un procédé de polissage chimico-mécanique d'un substrat, comprenant : la fourniture d'un substrat, le substrat étant une plaquette de semi- conducteurs à interconnexions en cuivre ; la fourniture d'une composition selon la présente invention ; la fourniture d'un ...

METHOD AND APPARATUS FOR RECYCLING AND REFINING OF PROPYLENE

Un procédé de recyclage et de raffinage du propylène est proposé selon la présente divulgation. La présente divulgation vise à résoudre le problème de la consommation élevée d'énergie de l'art antérieur. Un appareil de recyclage du propylène comprenant une première colonne de récupération de propylène (I), un ballon de détente (III), une deuxième colonne de récupération de propylène (IV), et une colonne de dépropanisation (II) selon la présente divulgation peut résoudre efficacement le problème, et être utilisé pour la fabrication industrielle de propylène récupéré à partir d'un appareil de production d'oxyde de propylène.

METHOD FOR ALLOCATING RESOURCES IN THE ACCESS NETWORK, BASE STATION, COMPUTER PROGRAM PRODUCT AND CORRESPONDING INFORMATION CARRIER

La présente invention se rapporte à un procédé d'allocation de porteuse et de détermination de puissance émise pour Mi communications montantes (UU) et Ni communications descendantes (DU) entre des mobiles half-duplex et une station de base i parmi L stations de base d'un réseau d'accès full-duplex. Une bande fréquentielle de K porteuses est allouée pour les L stations de base avec un accès au canal de transmission de type OFDMA. Pour maximiser un débit somme du réseau d'accès, le procédé considère le Lagrangien duale du débit somme en faisant apparaître dans son expression des variables {Ym} et λ multiplicatives respectivement d'une contrainte sur les puissances maximales émises par des mobiles {m} et d'une puissance maximale émise par une station de base i. Le procédé détermine de manière itérative l'ensemble des triplets porteuse et paires de puissance qui optimise l'expression duale pour les valeurs des variables {Ym} et λ.

Electronic device with cover having internal protruding portions for dispersing of sound

An exemplary electronic device includes a box, a speaker, and a micro structure. The box includes a shell and a cover disposed on the shell. The speaker is sandwiched between the shell and the cover. The micro structure includes a plurality of flat-bottomed protruding portions, a plurality of first pyramidal protruding portions, and a plurality of second pyramidal protruding portions.

Electronic device having detector window

An electronic device includes a body, a detector window, and a fixing mechanism for securing the detector window to the body. The detector window is capable of being inserted into the body in a first direction, and includes at least one hook member. The fixing mechanism includes at least one latching member, at least one first limiting member and at least one second limiting member. The at least one latching member hooks the at least one hook member to limit the movement of the detector window in the first direction. The at least one latching first limiting member and the at least one second limiting member respectively are arranged opposite sides of the latching member and respectively resisting against opposite sides of the at least one hook member to cooperatively limit the movement of the detector window in a second direction perpendicular to the first direction.

4-SUBSTITUTED-2-PHENOXY-PHENYLAMINE DELTA OPIOID RECEPTOR MODULATORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: 2. The compound of wherein Ris selected from the group consisting of{'sub': 1-4', '1-4', '1-4, 'i) phenyl optionally substituted with one to two substituents independently selected from the group consisting of Calkoxy, di(Calkyl)aminocarbonyl, and fluoro; such that only one di(C-alkyl)aminocarbonyl is present;'}ii) naphthyl;{'sub': 1-4', '1-4', '1-4, 'iii) pyridinyl optionally substituted with one substituent selected from the group consisting of Calkyl, Calkoxy, Calkylthio, fluoro, and cyano;'}iv) pyrimidin-5-yl;v) furanyl;vi) thienyl; and{'sub': '1-2', 'vii) di(Calkyl)aminocarbonyl.'}3. The compound of wherein Ris selected from the group consisting of{'sub': 1-4', '1-4, 'i) phenyl optionally substituted with one substituent selected from the group consisting of Calkoxy, di(Calkyl)aminocarbonyl, and fluoro;'}{'sub': 1-4', '1-4', '1-4, 'ii) pyridinyl optionally substituted with one substituent selected from the group consisting of Calkyl, Calkoxy, Calkylthio, fluoro, and cyano;'}iii) pyrimidin-5-yl; and{'sub': '1-2', 'iv) di(Calkyl)aminocarbonyl.'}4. The compound of wherein Ris selected from the group consisting ofi) phenyl optionally substituted with one methoxy substituent;{'sub': 1-4', '1-4', '1-4, 'ii) pyridinyl optionally substituted with one substituent selected from the group consisting of Calkyl, Calkoxy, Calkylthio, fluoro, and cyano;'}iii) pyrimidin-5-yl; and{'sub': '1-2', 'iv) di(Calkyl)aminocarbonyl.'}5. The compound of wherein Y is vinyl or a bond; or claim 1 , Y is O when Ris an optionally substituted phenyl.6. The compound of wherein Y is vinyl or a bond.7. The compound of wherein Ris phenyl optionally substituted with one to two substituents independently selected from the group consisting of Calkyl claim 1 , Calkoxy claim 1 , fluoro claim 1 , chloro claim 1 , and ...

True Color Liquid Crystal Displaying Device

A true color liquid crystal displaying device is disclosed in the present invention. The true color liquid crystal displaying device includes a light guide module, a LED light source, and a liquid crystal panel without a color filter. The light guide module includes a light guide body, an optical input portion and an emitting surface. The emitting surface includes an emitting area. The LED light source is disposed on the optical input portion of the light guide module for emitting RGB beams. The liquid crystal panel is disposed above the emitting surface of the light guide module. The emitting area aligns with a sub-pixel of the liquid crystal panel. The optical cable inside the light guide module guides the monochromatic beam from the LED light source to each corresponding sub-pixel of the liquid crystal panel, so that the RGB beams is the pixel of the true color performance. 1. A true color liquid crystal displaying device comprising:a light guide module, the light guide module comprising a light guide body, an optical input portion and an emitting surface, the emitting surface comprising an emitting area;a light emitting diode (LED) light source disposed on the optical input portion of the light guide module for emitting RGB beams; anda liquid crystal panel disposed above the emitting surface of the light guide module, the emitting area aligning with a sub-pixel of the liquid crystal panel, the beam from the LED light source being transmitted into the light guide module via the optical input portion, and being further transmitted into the liquid crystal panel via the light guide body and the emitting area on the emitting surface;wherein the liquid crystal panel does not comprise a color filter.2. The true color liquid crystal displaying device of claim 1 , wherein the LED light source is embedded in or outwardly disposed on the optical input portion of the light guide module claim 1 , an external optical cable is disposed between the LED light source and the ...

PRODUCTS AND METHODS FOR DELIVERY OF POLYNUCLEOTIDES BY ADENO-ASSOCIATED VIRUS FOR LYSOSOMAL STORAGE DISORDERS

The present invention relates to methods and materials useful for systemically delivering polynucleotides across the blood brain barrier using adeno-associated virus as a vector. For example, the present invention relates to methods and materials useful for systemically delivering α-N-acetylglucosamidinase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of these methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIB. As another example, the present invention relates to methods and materials useful for systemically delivering N-sulphoglucosamine sulfphohydrolase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of this second type of methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIA. 1. A method of delivering an α-N-acetylglucosamidinase polynucleotide across the blood-brain-barrier comprising the step of systemically administering a rAAV9 comprising a single-stranded genome including the polynucleotide to a patient.2. A method of delivering an α-N-acetylglucosamidinase polynucleotide to the central nervous system comprising the step of systemically administering a rAAV9 comprising a single-stranded genome including the polynucleotide to a patient.37.-. (canceled)8. A method of delivering an α-N-acetylglucosamidinase polynucleotide to the peripheral nervous system comprising the step of administering a rAAV9 comprising a single-stranded genome including the polynucleotide to a patient.910.-. (canceled)11. A method of treating mucopolysaccharidosis IIIB comprising the step of systemically administering a rAAV9 comprising a single-stranded genome including an α-N-acetylglucosamidinase polynucleotide to a patient.12. The method of any one of , , or wherein mannitol is administered prior to the administration of the rAAV.13. (canceled ...

PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds, and enantiomers, diastereomers, and pharmaceutically acceptable salts thereof, are represented by Formula (I) as follows: 2. The compound of wherein Group a) is an unsubstituted phenyl or an unsubstituted heteroaryl selected from the group consisting of thiazolyl claim 1 , isothiazolyl claim 1 , and 1H-pyrrolyl.3. The compound of wherein Group a) is an unsubstituted phenyl or an unsubstituted heteroaryl selected from the group consisting of thiazol-2-yl claim 1 , thiazol-4-yl claim 1 , thiazol-5-yl claim 1 , isothiazolyl claim 1 , 1H-pyrrol-2-yl claim 1 , and 1H-pyrrol-3-yl.4. The compound of wherein Group b) is selected from the group consisting ofi) phenyl;ii) a heteroaryl selected from the group consisting of benzoxazolyl, benzimidazolyl, benzothienyl, and indolyl;iii) phenylmethyl-phenyl wherein the phenyl group of phenylmethyl is unsubstituted or substituted with trifluoromethyl or fluoro; and [{'sub': b', 'b, 'wherein Group b) other than phenylmethyl-phenyl is unsubstituted or substituted with one or two substitutents independently selected from the group consisting of chloro, fluoro, methyl, and R; provided that no more than one substituent is R; and'}, {'sub': b', 'b, 'Ris selected from the group consisting of trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 4,4-difluorocyclohexyl, thienyl, pyridinyl, and phenyl; wherein said thienyl, pyridinyl, and phenyl of Rare unsubstituted or substituted with one or two substitutents independently selected from the group consisting of trifluoromethyl, methyl, chloro, and fluoro.'}], 'iv) 1,3-dihydro-3H-benzimidazol-2-on-yl;'}5. The compound of wherein Group b) is delected from the group consisting ofi) phenyl;ii) a heteroaryl selected from the group consisting of benzoxazolyl, benzimidazolyl, benzothienyl, and indolyl;iii) phenylmethyl-phenyl wherein the ...

AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: 118.-. (canceled)20. A pharmaceutical composition comprising a compound of and at least one of a pharmaceutically acceptable carrier claim 19 , a pharmaceutically acceptable excipient and a pharmaceutically acceptable diluent.21. A pharmaceutical composition of claim 20 , wherein the composition is a solid oral dosage form.22. A pharmaceutical composition of claim 20 , wherein the composition is a syrup claim 20 , an elixir or a suspension. This application claims priority to U.S. provisional patent application Nos. 61/171,658 and 61/171,649, each filed Apr. 22, 2009, which are hereby incorporated by reference in their entirety.The research and development of the invention described below was not federally sponsored.Cannabis sativa has been used for the treatment of pain for many years. Δ-tetrahydrocannabinol is a major active ingredient from Cannabis sativa and an agonist of cannabinoid receptors (Pertwee, 2008, 153, 199-215). Two cannabinoid G protein-coupled receptors have been cloned, cannabinoid receptor type 1 (CBMatsuda et al., 1990, 346, 561-4) and cannabinoid receptor type 2 (CBMunro et al., 1993, 365, 61-5). CBis expressed centrally in brain areas, such as the hypothalamus and nucleus accumbens as well as peripherally in the liver, gastrointestinal tract, pancreas, adipose tissue, and skeletal muscle (Di Marzo et al., 2007, 18, 129-140). CBis predominantly expressed in immune cells, such as monocytes (Pacher et al., 2008, 294, H1133-H1134), and under certain conditions, also in the brain (Benito et al., 2008, 153, 277-285) and in skeletal (Cavuoto et al., 2007, 364, 105-110) and cardiac (Hajrasouliha et al., 2008, 579, 246-252) muscle. An abundance of pharmacological, anatomical and electrophysiological data, using synthetic agonists, indicate that increased ...

AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: 119.-. (canceled)21. A pharmaceutical composition comprising a compound of and at least one of a pharmaceutically acceptable carrier claim 20 , a pharmaceutically acceptable excipient claim 20 , and a pharmaceutically acceptable diluent.22. A pharmaceutical composition of claim 21 , wherein the composition is a solid oral dosage form.23. A pharmaceutical composition of claim 21 , wherein the composition is a syrup claim 21 , an elixir claim 21 , or a suspension. This application claims priority to U.S. provisional patent application Nos. 61/171,658 and 61/171,649, each filed Apr. 22, 2009, which are hereby incorporated by reference in their entirety.The research and development of the invention described below was not federally sponsored.has been used for the treatment of pain for many years. Δ-tetrahydrocannabinol is a major active ingredient from and an agonist of cannabinoid receptors (Pertwee, 2008, 153, 199-215). Two cannabinoid G protein-coupled receptors have been cloned, cannabinoid receptor type 1 (CBMatsuda et al., 1990, 346, 561-4) and cannabinoid receptor type 2 (CBMunro et al., 1993, 365, 61-5). CBis expressed centrally in brain areas, such as the hypothalamus and nucleus accumbens as well as peripherally in the liver, gastrointestinal tract, pancreas, adipose tissue, and skeletal muscle (Di Marzo et al., 2007, 18, 129-140). CBis predominantly expressed in immune cells, such as monocytes (Pacher et al., 2008, 294, H1133-H1134), and under certain conditions, also in the brain (Benito et al., 2008, 153, 277-285) and in skeletal (Cavuoto et al., 2007, 364, 105-110) and cardiac (Hajrasouliha et al., 2008, 579, 246-252) muscle. An abundance of pharmacological, anatomical and electrophysiological data, using synthetic agonists, indicate that increased cannabinoid ...

AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: 117.-. (canceled)19. A pharmaceutical composition comprising a compound of and at least one of a pharmaceutically acceptable carrier claim 18 , a pharmaceutically acceptable excipient and a pharmaceutically acceptable diluent.20. A pharmaceutical composition of claim 19 , wherein the composition is a solid oral dosage form.21. A pharmaceutical composition of claim 19 , wherein the composition is a syrup claim 19 , an elixir or a suspension. This application claims priority to U.S. provisional patent application Nos. 61/171,658 and 61/171,649, each filed Apr. 22, 2009, which are hereby incorporated by reference in their entirety.The research and development of the invention described below was not federally sponsored.has been used for the treatment of pain for many years. Δ-tetrahydrocannabinol is a major active ingredient from and an agonist of cannabinoid receptors (Pertwee, 2008, 153, 199-215). Two cannabinoid G protein-coupled receptors have been cloned, cannabinoid receptor type 1 (CBMatsuda et al., Nature, 1990, 346, 561-4) and cannabinoid receptor type 2 (CBMunro et al., 1993, 365, 61-5). CBis expressed centrally in brain areas, such as the hypothalamus and nucleus accumbens as well as peripherally in the liver, gastrointestinal tract, pancreas, adipose tissue, and skeletal muscle (Di Marzo et al., 2007, 18, 129-140). CBis predominantly expressed in immune cells, such as monocytes (Pacher et al., 2008, 294, H1133-H1134), and under certain conditions, also in the brain (Benito et al., 2008, 153, 277-285) and in skeletal (Cavuoto et al., 2007, 364, 105-110) and cardiac (Hajrasouliha et al., 2008, 579, 246-252) muscle. An abundance of pharmacological, anatomical and electrophysiological data, using synthetic agonists, indicate that increased cannabinoid signaling through CB/ ...

AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: 118.-. (canceled)20. A pharmaceutical composition comprising a compound of and at least one of a pharmaceutically acceptable carrier claim 19 , a pharmaceutically acceptable excipient and a pharmaceutically acceptable diluent.21. A pharmaceutical composition of claim 20 , wherein the composition is a solid oral dosage form.22. A pharmaceutical composition of claim 20 , wherein the composition is a syrup claim 20 , an elixir or a suspension. This application claims priority to U.S. provisional patent application Nos. 61/171,658 and 61/171,649, each filed Apr. 22, 2009, which are hereby incorporated by reference in their entirety.The research and development of the invention described below was not federally sponsored.has been used for the treatment of pain for many years. Δ-tetrahydrocannabinol is a major active ingredient from and an agonist of cannabinoid receptors (Pertwee, 2008, 153, 199-215). Two cannabinoid G protein-coupled receptors have been cloned, cannabinoid receptor type 1 (CBMatsuda et al., 1990, 346, 561-4) and cannabinoid receptor type 2 (CBMunro et al., 1993, 365, 61-5). CBis expressed centrally in brain areas, such as the hypothalamus and nucleus accumbens as well as peripherally in the liver, gastrointestinal tract, pancreas, adipose tissue, and skeletal muscle (Di Marzo et al., 2007, 18, 129-140). CBis predominantly expressed in immune cells, such as monocytes (Pacher et al., 2008, 294, H1133-H1134), and under certain conditions, also in the brain (Benito et al., 2008, 153, 277-285) and in skeletal (Cavuoto et al., 2007, 364, 105-110) and cardiac (Hajrasouliha et al., 2008, 579, 246-252) muscle. An abundance of pharmacological, anatomical and electrophysiological data, using synthetic agonists, indicate that increased cannabinoid signaling through CB/ ...

AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: 118-. (canceled)20. A pharmaceutical composition comprising a compound of and at least one of a pharmaceutically acceptable carrier claim 19 , a pharmaceutically acceptable excipient claim 19 , and a pharmaceutically acceptable diluent.21. A pharmaceutical composition of claim 20 , wherein the composition is a solid oral dosage form.22. A pharmaceutical composition of claim 20 , wherein the composition is a syrup claim 20 , an elixir claim 20 , or a suspension. This application claims priority to U.S. provisional patent application Nos. 61/171,658 and 61/171,649, each filed Apr. 22, 2009, which are hereby incorporated by reference in their entirety.The research and development of the invention described below was not federally sponsored.has been used for the treatment of pain for many years. Δ-tetrahydrocannabinol is a major active ingredient from and an agonist of cannabinoid receptors (Pertwee, 2008, 153, 199-215). Two cannabinoid G protein-coupled receptors have been cloned, cannabinoid receptor type 1 (CBMatsuda et al., 1990, 346, 561-4) and cannabinoid receptor type 2 (CBMunro et al., 1993, 365, 61-5). CBis expressed centrally in brain areas, such as the hypothalamus and nucleus accumbens as well as peripherally in the liver, gastrointestinal tract, pancreas, adipose tissue, and skeletal muscle (Di Marzo et al., 2007, 18, 129-140). CBis predominantly expressed in immune cells, such as monocytes (Pacher et al., 2008, 294, H1133-H1134), and under certain conditions, also in the brain (Benito et al., 2008, 153, 277-285) and in skeletal (Cavuoto et al., 2007, 364, 105-110) and cardiac (Hajrasouliha et al., 2008, 579, 246-252) muscle. An abundance of pharmacological, anatomical and electrophysiological data, using synthetic agonists, indicate that increased cannabinoid ...

AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: 117.-. (canceled)19. A pharmaceutical composition comprising a compound of and at least one of a pharmaceutically acceptable carrier claim 18 , a pharmaceutically acceptable excipient and a pharmaceutically acceptable diluent.20. A pharmaceutical composition of claim 19 , wherein the composition is a solid oral dosage form.21. A pharmaceutical composition of claim 19 , wherein the composition is a syrup claim 19 , an elixir or a suspension. This application claims priority to U.S. provisional patent application Nos. 61/171,658 and 61/171,649, each filed Apr. 22, 2009, which are hereby incorporated by reference in their entirety.The research and development of the invention described below was not federally sponsored.has been used for the treatment of pain for many years. Δ-tetrahydrocannabinol is a major active ingredient from and an agonist of cannabinoid receptors (Pertwee, 2008, 153, 199-215). Two cannabinoid G protein-coupled receptors have been cloned, cannabinoid receptor type 1 (CBMatsuda et al., 1990, 346, 561-4) and cannabinoid receptor type 2 (CBMunro et al., 1993, 365, 61-5). CBis expressed centrally in brain areas, such as the hypothalamus and nucleus accumbens as well as peripherally in the liver, gastrointestinal tract, pancreas, adipose tissue, and skeletal muscle (Di Marzo et al., 2007, 18, 129-140). CBis predominantly expressed in immune cells, such as monocytes (Pacher et al., 2008, 294, H1133-H1134), and under certain conditions, also in the brain (Benito et al., 2008, 153, 277-285) and in skeletal (Cavuoto et al., 2007, 364, 105-110) and cardiac (Hajrasouliha et al., 2008, 579, 246-252) muscle. An abundance of pharmacological, anatomical and electrophysiological data, using synthetic agonists, indicate that increased cannabinoid signaling through CB/ ...

AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: 121.-. (canceled)23. A pharmaceutical composition comprising a compound of and at least one of a pharmaceutically acceptable carrier claim 22 , a pharmaceutically acceptable excipient claim 22 , and a pharmaceutically acceptable diluent.24. A pharmaceutical composition of claim 23 , wherein the composition is a solid oral dosage form.25. A pharmaceutical composition of claim 23 , wherein the composition is a syrup claim 23 , an elixir claim 23 , or a suspension.26. The compound of wherein Y is thiazol-2-yl claim 22 , Z is 1-(4-fluorophenyl)-indol-5-yl claim 22 , and s is 0.28. A pharmaceutical composition comprising the compound of and at least one of a pharmaceutically acceptable carrier claim 27 , a pharmaceutically acceptable excipient claim 27 , and a pharmaceutically acceptable diluent.29. A pharmaceutical composition of claim 28 , wherein the composition is a solid oral dosage form.30. A pharmaceutical composition of claim 28 , wherein the composition is a syrup claim 28 , an elixir claim 28 , or a suspension. This application claims priority to U.S. provisional patent application Nos. 61/171,658 and 61/171,649, each filed Apr. 22, 2009, which are hereby incorporated by reference in their entirety.The research and development of the invention described below was not federally sponsored.has been used for the treatment of pain for many years. Δ-tetrahydrocannabinol is a major active ingredient from and an agonist of cannabinoid receptors (Pertwee, 2008, 153, 199-215). Two cannabinoid G protein-coupled receptors have been cloned, cannabinoid receptor type 1 (CBMatsuda et al., 1990, 346, 561-4) and cannabinoid receptor type 2 (CBMunro et al., 1993, 365, 61-5). CBis expressed centrally in brain areas, such as the hypothalamus and nucleus accumbens as well as peripherally in ...

PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLCEROL LIPASE INHIBITORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds, and enantiomers, diastereomers, and pharmaceutically acceptable salts thereof, are represented by Formula (I) as follows: 116.-. (canceled)18. A pharmaceutical composition comprising a compound of and at least one of a pharmaceutically acceptable carrier claim 17 , a pharmaceutically acceptable excipient and a pharmaceutically acceptable diluent.19. The pharmaceutical composition of claim 18 , wherein the composition is a solid oral dosage form.20. The pharmaceutical composition of claim 18 , wherein the composition is a syrup claim 18 , an elixir or a suspension. Not applicable.The research and development of the invention described below was not federally sponsored.has been used for the treatment of pain for many years. Δ-tetrahydrocannabinol is a major active ingredient from and an agonist of cannabinoid receptors (Pertwee, 2008, 153, 199-215). Two cannabinoid G protein-coupled receptors have been cloned, cannabinoid receptor type 1 (CBMatsuda et al., 1990, 346, 561-4) and cannabinoid receptor type 2 (CBMunro et al., 1993, 365, 61-5). CBis expressed centrally in brain areas, such as the hypothalamus and nucleus accumbens as well as peripherally in the liver, gastrointestinal tract, pancreas, adipose tissue, and skeletal muscle (Di Marzo et al., 2007, 18, 129-140). CBis predominantly expressed in immune cells, such as monocytes (Pacher et al., 2008, 294, H1133-H1134), and under certain conditions, also in the brain (Benito et al., 2008, 153, 277-285) and in skeletal (Cavuoto et al., 2007, 364, 105-110) and cardiac (Hajrasouliha et al., 2008, 579, 246-252) muscle. An abundance of pharmacological, anatomical and electrophysiological data, using synthetic agonists, indicate that increased cannabinoid signaling through CB/CBpromotes analgesia in tests of acute nociception and suppresses hyperalgesia in models of chronic ...

PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: 125-. (canceled)27. The method of wherein the mild to severe pain is due to a disease or condition selected from the group consisting of osteoarthritis claim 26 , rheumatoid arthritis claim 26 , fibromyalgia claim 26 , migraine claim 26 , headache claim 26 , toothache claim 26 , burn claim 26 , sunburn claim 26 , snake bite claim 26 , spider bite claim 26 , insect sting claim 26 , neurogenic bladder claim 26 , benign prostatic hypertrophy claim 26 , interstitial cystitis claim 26 , rhinitis claim 26 , contact dermatitis/hypersensitivity claim 26 , itch claim 26 , eczema claim 26 , pharyngitis claim 26 , mucositis claim 26 , enteritis claim 26 , cellulites claim 26 , causalgia claim 26 , sciatic neuritis claim 26 , mandibular joint neuralgia claim 26 , peripheral neuritis claim 26 , polyneuritis claim 26 , stump pain claim 26 , phantom limb pain claim 26 , post operative ileus claim 26 , cholecystitis claim 26 , postmastectomy pain syndrome claim 26 , oral neuropathic pain claim 26 , Charcot's pain claim 26 , reflex sympathetic dystrophy claim 26 , Guillain Barre syndrome claim 26 , meralgia paresthetica claim 26 , burning mouth syndrome claim 26 , cluster headache claim 26 , migraine headache claim 26 , peripheral neuropathy claim 26 , bilateral peripheral neuropathy claim 26 , diabetic neuropathy claim 26 , optic neuritis claim 26 , postfebrile neuritis claim 26 , migrating neuritis claim 26 , segmental neuritis claim 26 , Gombault's neuritis claim 26 , neuronitis claim 26 , cervicobrachial neuralgia claim 26 , cranial neuralgia claim 26 , geniculate neuralgia claim 26 , glossopharyngial neuralgia claim 26 , migrainous neuralgia claim 26 , idiopathic neuralgia claim 26 , intercostals neuralgia claim 26 , mammary neuralgia claim 26 , Morton's neuralgia claim 26 , nasociliary ...

Negative pressure wound therapy system with a buffering unit

A negative pressure wound therapy system has a buffering unit connected between an actuator and a wound dressing. The buffering unit has similar physical condition with the wound, and consumes its negative pressure to compensate for the negative pressure loss in the wound to resist the pressure rise in the wound during slight leakage. The buffering unit also keeps the actuator from directly operating on the wound to reduce the pain of the patient while lowering the pressure in the wound.

PRODUCTS AND METHODS FOR DELIVERY OF POLYNUCLEOTIDES BY ADENO-ASSOCIATED VIRUS FOR LYSOSOMAL STORAGE DISORDERS

The present invention relates to methods and materials useful for systemically delivering polynucleotides across the blood brain barrier using adeno-associated virus as a vector. For example, the present invention relates to methods and materials useful for systemically delivering α-N-acetylglucosamidinase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of these methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIB. As another example, the present invention relates to methods and materials useful for systemically delivering N-sulphoglucosamine sulfphohydrolase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of this second type of methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIA. 117-. (canceled)18. A method of delivering an N-sulphoglucosamine sulphohydrolase polynucleotide to the central nervous system comprising the step of systemically administering a rAAV9 or rh74 comprising a self-complementary genome including the polynucleotide to a patient.1926-. (canceled)27. A method of treating mucopolysaccharidosis IIIA comprising the step of systemically administering a rAAV9 or rh74 comprising a self-complementary genome including an N-sulphoglucosamine sulphohydrolase polynucleotide to a patient.2831-. (canceled)32. The method of wherein mannitol is administered prior to the administration of the rAAV.33. The method of wherein mannitol is administered prior to the administration of the rAAV.34. The method of wherein the sequence of the N-sulphoglucosamine sulphohydrolase polynucleotide is set out in SEQ ID NO: 3.35. The method of wherein the sequence of the N-sulphoglucosamine sulphohydrolase polynucleotide is set out in SEQ ID NO: 3.36. The method of wherein the sequence of the N-sulphoglucosamine sulphohydrolase ...

PRODUCTS AND METHODS FOR DELIVERY OF POLYNUCLEOTIDES BY ADENO-ASSOCIATED VIRUS FOR LYSOSOMAL STORAGE DISORDERS

The present invention relates to methods and materials useful for systemically delivering polynucleotides across the blood brain barrier using adeno-associated virus as a vector. For example, the present invention relates to methods and materials useful for systemically delivering α-N-acetylglucosamidinase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of these methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIB. As another example, the present invention relates to methods and materials useful for systemically delivering N-sulphoglucosamine sulfphohydrolase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of this second type of methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIA. 131-. (canceled)32. A method of treating mucopolysaccharidosis IIIB (MPS IIIB) in a patient in need thereof comprising intravenously administering an rAAV9 comprising a single-stranded genome expressing an α-N-acetylglucosaminidase (NAGLU) polynucleotide effective to:(a) alleviate lysosomal storage lesions in the central nervous system, peripheral nervous system and other somatic tissues,(b) alleviate astrocytosis and neurodegeneration in the central nervous system and peripheral nervous system, and(c) effect widespread somatic restoration of α-N-acetylglucosaminidase (NAGLU) activity,wherein mannitol is not administered to the patient prior to administering the rAAV9.33. The method of claim 32 , wherein the effective amount of rAAV9 administered is at least about 1×10vg/kg.34. The method of claim 32 , wherein the patient exhibits symptoms of neuropathology.35. The method of claim 32 , further comprising testing the patient for neuroinflammation after the rAAV9 has been administered.36. The method of claim 32 , wherein the treatment further comprises ...

Systems and methods for use with internal combustion engines and vehicles comprising the same

Systems, methods, and vehicles for use with internal combustion engines comprising combustion chambers that produce exhaust gases that include a Stirling engine having a hot side and a cold side with the hot side being in thermal contact with exhaust gases produced by the internal combustion engine. The Stirling engine is configured to be powered by heat from the exhaust gases during operation of the internal combustion engine, and a compressor powered by the Stirling engine is configured to provide compressed air to combustion chambers of the internal combustion engine.

RILUZOLE PRODRUGS AND THEIR USE

Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process. 3. A composition comprising an effective amount of at least one compound according to and at least one excipient.4. A method for treating or preventing cancer claim 1 , said method comprising administering to a subject an effective amount of at least one compound according to .5. The method of claim 4 , wherein the at least one compound is administered in a composition further comprising at least one excipient.6. The method of claim 5 , wherein the at least one compound is administered in a composition further comprising an anticancer agent.7. The method of wherein the anticancer agent is selected from the group consisting of Vemurafenib claim 6 , Ipilimumab claim 6 , Masitinib claim 6 , Sorafenib claim 6 , Lenalidomide claim 6 , Oblimersen claim 6 , Trametinib claim 6 , Dabrafenib claim 6 , RO5185426 claim 6 , Veliparib claim 6 , Bosentan claim 6 , YM155 claim 6 , CNTO 95 claim 6 , CR011-vcMMAE claim 6 , CY503 claim 6 , Lenvatinib claim 6 , Avastin claim 6 , Tasidotin claim 6 , Ramucirumab claim 6 , IPI-504 claim 6 , Tasisulam claim 6 , KW2871 claim 6 , MPC-6827 claim 6 , RAF265 claim 6 , Dovitinib claim 6 , Everolimus claim 6 , MEK162 claim 6 , BKM120 claim 6 , Nilotinib claim 6 , Reolysin claim 6 , 825A claim 6 , Tremelimumab claim 6 , PI-88 claim 6 , Elesclomol claim 6 , STA9090 claim 6 , and Allovectin-7.8. The method of wherein the cancer is selected from the group consisting of melanoma claim 6 , nonmelanoma skin cancer claim 6 , skin cancer claim 6 , ovarian cancer claim 6 , cervical cancer claim ...

PRODRUGS RILUZOLE AND THEIR METHOD OF USE

Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process. 18. A compound according to selected from the group consisting of:2-(methylamino)-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl) acetamide;(S)—N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)pyrrolidine-2-carboxamide;(R)-2-amino-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl) propanamide;3-amino-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl) propanamide;1-amino-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl) cyclopropane-1-carboxamide;(S)—N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)azetidine-2-carboxamide;2-amino-2-methyl-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl) propanamide;(S)-2-(methylamino)-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl) propanamide;(R)-2-(methylamino)-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl) propanamide;(R)-2-amino-3-hydroxy-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl) propanamide;(R)-2-amino-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)pent-4-ynamide;(S)-2-amino-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)pent-4-ynamide;(R)—N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)pyrrolidine-2-carboxamide;1-amino-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)cyclobutane-1-carboxamide;(S)-2-amino-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl) pentanamide;(R)-2-amino-3-methyl-N-(2-oxo-2 ...

BINDING MOLECULE SPECIFIC FOR CD73 AND USE OF BINDING MOLECULE

A binding molecule specific for CD73 and a use of the binding molecule. Specifically, provided are a separate antibody binding CD73 and inhibiting the activity of CD73 or an antigen binding part of the separate antibody, and a use of the separate antibody or the antigen binding part thereof in treatment of diseases; also provided are a nucleic acid molecule encoding the separate antibody or the antigen binding part thereof, an expression vector for expressing the separate antibody or the antigen binding part thereof, a host cell, and a preparation method.

INDENE DERIVATIVES AND USES THEREOF

The present invention relates to compounds of formula (I): 2. The compound according to claim 1 , wherein Rand R claim 1 , independently of each other claim 1 , are hydrogen claim 1 , hydroxyl claim 1 , alkyl claim 1 , alkoxy claim 1 , methoxy-acetate claim 1 , phosphate claim 1 , valine claim 1 , Gly-Ser claim 1 , —OC(O)CHOC(O)CH claim 1 , —OC(O)CHOCH claim 1 , —OCHC(O)C(CH) claim 1 , —OCHC(O)NHor —OCHC(O)OH.3. The compound according to claim 1 , wherein Rand R claim 1 , together with the carbon atoms to which they are attached claim 1 , form a 5 to 6-membered ring with one or two ring carbons replaced independently by oxygen or nitrogen.4. The compound according to claim 1 , wherein Ris hydroxyl.5. The compound according to claim 1 , wherein R is hydroxyl.6. The compound according to claim 1 , wherein both Rand Rare hydroxyl.7. The compound according to claim 1 , wherein Ris alkoxy.8. The compound according to claim 1 , wherein Ris alkoxy.9. The compound according to claim 1 , wherein both Rand Rare alkoxy.10. The compound according to claim 1 , wherein Ris hydrogen claim 1 , hydroxyl claim 1 , halogen claim 1 , cyano claim 1 , —COOH claim 1 , —C(O)NH claim 1 , —C(O)CHCH claim 1 , —C(O)-alkoxy claim 1 , alkyl claim 1 , alkoxy claim 1 , halo-lower alkyl claim 1 , carboxyl claim 1 , amide claim 1 , ester or nitrile.11. The compound according to claim 1 , wherein Ris amide.12. The compound according to claim 1 , wherein Ris —CF.13. The compound according to claim 1 , wherein Ris alkenyl.14. The compound according to claim 1 , wherein Ris alkenyl optionally mono or bi-substituted independently with hydrogen claim 1 , halogen claim 1 , hydroxyl claim 1 , —OCH-phenyl claim 1 , cycloalkyl claim 1 , —OCH-halophenyl or —OCH-phenylhaloalkyl.16. A pharmaceutical composition claim 1 , comprising a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutically acceptable carrier.17. A ...

Optical Lens

The invention relates to an optical lens utilized for disposing above a light source. The optical lens has rotational symmetry relative to the central axis thereof. The central axis of the optical lens aligns with the center of the light source. The optical lens includes a bottom surface, an emergence surface with arc shape, an incidence surface with arc and concave shape, a curved surface with annular and concave shape and a light diffusing structure. The emergence surface connects a side of the bottom surface. The incidence surface connects another side of the bottom surface and lies in the middle of the bottom surface. The curved surface lies on the bottom surface and connects the incidence surface. The light diffusing structure is disposed on the curved surface. The invention improves the distribution of light projected on a light receiving surface and prevents a bright circle formed on the light receiving surface as a result of a gap that is formed by assembly tolerance of the optical lens and the light source. 1. An optical lens , utilized for positioning above a light source , having rotational symmetry relative to a central axis thereof aligning with a center of the light source and comprising:a bottom surface;an emergence surface with arc shape connecting a side of the bottom surface;an incidence surface with arc and concave shape connecting another side of the bottom surface and lying in the middle of the bottom surface;a curved surface with annular and concave shape lying on the bottom surface and connecting the incidence surface; anda light diffusing structure disposed on the curved surface.2. The optical lens of claim 1 , wherein the light diffusing structure includes a plurality of convex points or a plurality of concave points distributed continuously.3. The optical lens of claim 2 , wherein a radius of the convex point or a radius of the concave point is less than 0.5 mm.4. The optical lens of claim 1 , wherein an edge of the bottom surface includes ...

RILUZOLE PRODRUGS AND THEIR USE

Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process. 2. The method according to claim 1 , wherein Ris H.3. The method according to claim 1 , wherein the compound is selected from the group consisting of(S)-2-amino-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)propanamide;(R)-2-amino-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)propanamide;(S)-2-amino-3-methyl-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)butanamide;(R)-2-amino-3-methyl-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)butanamide;(S)-2-amino-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)-3-phenylpropanamide;(R)-2-amino-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)-3-phenylpropanamide;(S)-2-amino-4-methyl-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)pentanamide;(R)-2-amino-4-methyl-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)pentanamide;(S)-2-amino-3-hydroxy-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)propanamide;(R)-2-amino-3-hydroxy-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)propanamide;2-(2-aminoacetamido)-N-methyl-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)acetamide;or a pharmaceutically ...

FABRICATION METHOD AND FABRICATION ASSEMBLY FOR FLEXIBLE DISPLAY SUBSTRATE

A fabrication method and a fabrication assembly for a flexible display substrate are provided. The fabrication assembly for a flexible display substrate includes: a rigid base substrate, including a first engaging structure being on a surface of the rigid base substrate; and a protective film, including a first surface and a second surface opposite to each other, and including a second engaging structure being on the first surface. The second surface of the protective film is configured to be attached to a flexible base substrate; and the rigid base substrate and the protective film are configured to be detachably connected with each other by the first engaging structure and the second engaging structure. 1. A fabrication assembly for a flexible display substrate , comprising:a rigid base substrate, comprising a first engaging structure being provided on a surface of the rigid base substrate; anda protective film, comprising a first surface and a second surface opposite to each other, and comprising a second engaging structure being provided on the first surface,wherein the second surface of the protective film is configured to be attached to a flexible base substrate; andthe rigid base substrate and the protective film are configured to be detachably connected with each other by the first engaging structure and the second engaging structure.2. The assembly according to claim 1 , wherein the first engaging structure and the second engaging structure are both tenon-mortise structures.3. The assembly according to claim 1 , wherein the first engaging structure comprises a plurality of first bar-shaped tenons and a plurality of first bar-shaped mortises claim 1 , and the second engaging structure comprises a plurality of second bar-shaped tenons and a plurality of second bar-shaped mortises;one of the plurality of first bar-shaped mortises is provided between two adjacent first bar-shaped tenons, and one of the plurality of second bar-shaped mortises is provided between ...

Digitized Artificial Nail and Production Method

A production method of a digitized artificial nail for a nail of a user includes the steps of: (a) scanning the nail of the user to construct an irregular digitized user nail model; (b) data sampling to convert the irregular digitized user nail model into a regular digitized artificial nail model which is a regular three dimensional grid surface, and topology deformation of the regular three dimensional grid surface to form a digitized artificial nail model; (c) matching an artificial nail shape selected by the user with the digitized artificial nail model to obtain a desired artificial nail model; (d) customizing the digitized artificial nail model; and (e) three dimensional printing a digitized artificial nail in response to the digitized artificial nail model. 1. A production method of a digitized artificial nail for a nail of a user , comprising the steps of:(a) scanning the nail of the user to construct an irregular digitized user nail model;(b) data sampling to convert said irregular digitized user nail model into a regular digitized artificial nail model which is a regular three dimensional grid surface, and topology deformation of said regular three dimensional grid surface to form a digitized artificial nail model;(c) matching an artificial nail shape selected by the user with said digitized artificial nail model;(d) customizing the digitized artificial nail model; and(e) three dimensional printing a digitized artificial nail in response to said digitized artificial nail model.2. The production method claim 1 , as recited in claim 1 , wherein the step (a) comprises the steps of:(a.1) projecting structure light to scan a finger of the user to obtain scanned data of a finger model; and(a.2) capturing a user nail image, determining a plurality of three dimensional coordinates at different points on a nail surface of the user according to a curvature change of a nail surface in said user nail image, obtaining irregular user nail point cloud data via said ...

AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: 120-. (canceled)22. A pharmaceutical composition comprising a compound of and at least one of a pharmaceutically acceptable carrier claim 21 , a pharmaceutically acceptable excipient claim 21 , and a pharmaceutically acceptable diluent.23. A pharmaceutical composition of claim 22 , wherein the composition is a solid oral dosage form.24. A pharmaceutical composition of claim 22 , wherein the composition is a syrup claim 22 , an elixir claim 22 , or a suspension.25. The compound of wherein Y is thiazol-4-yl claim 21 , Z is 3-chloro-6-trifluoromethyl-benzothien-2-yl claim 21 , and s is 0.27. A pharmaceutical composition comprising the compound of and at least one of a pharmaceutically acceptable carrier claim 26 , a pharmaceutically acceptable excipient claim 26 , and a pharmaceutically acceptable diluent.28. A pharmaceutical composition of claim 27 , wherein the composition is a solid oral dosage form.29. A pharmaceutical composition of claim 27 , wherein the composition is a syrup claim 27 , an elixir claim 27 , or a suspension. This application claims priority to U.S. provisional patent application Nos. 61/171,658 and 61/171,649, each filed Apr. 22, 2009, which are hereby incorporated by reference in their entirety.The research and development of the invention described below was not federally sponsored.Cannabis sativa has been used for the treatment of pain for many years. Δ-tetrahydrocannabinol is a major active ingredient from Cannabis sativa and an agonist of cannabinoid receptors (Pertwee, 2008, 153, 199-215). Two cannabinoid G protein-coupled receptors have been cloned, cannabinoid receptor type 1 (CBMatsuda et al., 1990, 346, 561-4) and cannabinoid receptor type 2 (CBMunro et al., 1993, 365, 61-5). CBis expressed centrally in brain areas, such as the hypothalamus and ...

PRODUCTS AND METHODS FOR DELIVERY OF POLYNUCLEOTIDES BY ADENO-ASSOCIATED VIRUS FOR LYSOSOMAL STORAGE DISORDERS

The present invention relates to methods and materials useful for systemically delivering polynucleotides across the blood brain barrier using adeno-associated virus as a vector. For example, the present invention relates to methods and materials useful for systemically delivering α-N-acetylglucosamidinase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of these methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIB. As another example, the present invention relates to methods and materials useful for systemically delivering N-sulphoglucosamine sulfphohydrolase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of this second type of methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIA. 116-. (canceled)17. A method of delivering an N-sulphoglucosamine sulphohydrolase polynucleotide to a patient comprising the step of systemically administering a rAAV9 or rh74 comprising a self-complementary genome including the polynucleotide to a patient.1826.-. (canceled)27. A method of treating mucopolysaccharidosis IIIA comprising the step of systemically administering a rAAV9 or rh74 comprising a self-complementary genome including an N-sulphoglucosamine sulphohydrolase polynucleotide to a patient.28. The method of or wherein mannitol is administered prior to the administration of the rAAV.29. The method of any one of , or wherein the sequence of the N-sulphoglucosamine sulphohydrolase polynucleotide is set out in SEQ ID NO: 3.30. A rAAV9 or rh74 comprising a genome encoding N-sulphoglucosamine sulphohydrolase.31. A composition comprising the rAAV9 or rh74 of .32. The rAAV9 or rh74 of wherein the sequence of the N-sulphoglucosamine sulphohydrolase polynucleotide is set out in SEQ ID NO: 3.33. The composition of wherein the sequence of the N- ...

INDENE DERIVATIVES AND USES THEREOF

The present invention relates to compounds of formula (I): including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, cancer. 2. The compound according to claim 1 , wherein Rand R claim 1 , independently of each other claim 1 , are hydrogen claim 1 , hydroxyl claim 1 , alkyl claim 1 , alkoxy claim 1 , methoxy-acetate claim 1 , phosphate claim 1 , valine claim 1 , Gly-Ser claim 1 , —OC(O)CHOC(O)CH claim 1 , —OC(O)CHOCH claim 1 , —OCHC(O)C(CH) claim 1 , —OCHC(O)NHor —OCHC(O)OH.3. The compound according to claim 1 , wherein Rand R claim 1 , together with the carbon atoms to which they are attached claim 1 , form a 5 to 6-membered ring with one or two ring carbons replaced independently by oxygen or nitrogen.4. The compound according to claim 1 , wherein Ris hydroxyl.5. The compound according to claim 1 , wherein Ris hydroxyl.6. The compound according to claim 1 , wherein both Rand Rare hydroxyl.7. The compound according to claim 1 , wherein Ris alkoxy.8. The compound according to claim 1 , wherein Ris alkoxy.9. The compound according to claim 1 , wherein both Rand Rare alkoxy.10. The compound according to claim 1 , wherein Ris hydrogen claim 1 , hydroxyl claim 1 , halogen claim 1 , cyano claim 1 , —COOH claim 1 , —C(O)NH claim 1 , —C(O)CHCH claim 1 , —C(O)-alkoxy claim 1 , alkyl claim 1 , alkoxy claim 1 , halo-lower alkyl claim 1 , carboxyl claim 1 , amide claim 1 , ester or nitrile.11. The compound according to claim 1 , wherein Ris amide.12. The compound according to claim 1 , wherein Ris —CF.13. The compound according to claim 1 , wherein Ris alkenyl.14. The compound according to claim 1 , wherein Ris alkenyl optionally mono or bi-substituted independently with hydrogen claim 1 , halogen claim 1 , hydroxyl claim 1 , —OCH-phenyl claim 1 , cycloalkyl claim 1 , —OCH— halophenyl or —OCH-phenylhaloalkyl.16. A pharmaceutical composition claim 1 , comprising a therapeutically effective amount of a ...

METHOD AND APPARATUS FOR GENERATING BACKGROUND-FREE IMAGE, DEVICE, AND MEDIUM

Embodiments of the present disclosure provide a method and apparatus for generating a background-free image, a device, and a medium. The method may include: determining an image proportion of a target subject in an original image; clipping, in response to the image proportion being less than a preset threshold, a subject region image corresponding to the target subject from the original image; determining a corresponding subject region mask based on the subject region image; and synthesizing the subject region mask and the subject region image to generate a background-free image corresponding to the original image. 1. A method for generating a background-free image , comprising:determining an image proportion of a target subject in an original image;clipping, in response to the image proportion being less than a preset threshold, a subject region image corresponding to the target subject from the original image;determining a corresponding subject region mask based on the subject region image; andsynthesizing the subject region mask and the subject region image to generate a background-free image corresponding to the original image.2. The method according to claim 1 , wherein the determining an image proportion of a target subject in an original image comprises:performing saliency detection on the original image to obtain an initial mask of the original image;binarizing the initial mask of the original image to obtain a binarized mask of the original image; andcomputing the image proportion of the target subject in the original image based on an area of a target subject region in the binarized mask of the original image and an area of the original image.3. The method according to claim 2 , wherein after the computing the image proportion of the target subject in the original image based on an area of a target subject region in the binarized mask of the original image and an area of the original image claim 2 , the method further comprises:generating a tripartite ...

Products and Methods for Delivery of Polynucleotides by Adeno-Associated Virus for Lysosomal Storage Disorders

The present invention relates to methods and materials useful for systemically delivering polynucleotides across the blood brain barrier using adeno-associated virus as a vector. For example, the present invention relates to methods and materials useful for systemically delivering α-N-acetylglucosamidinase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of these methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIB. As another example, the present invention relates to methods and materials useful for systemically delivering N-sulphoglucosamine sulfphohydrolase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of this second type of methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIA. 1. A method of delivering an α-N-acetylglucosamidinase polynucleotide across the blood-brain-barrier comprising the step of systemically administering a rAAV9 comprising a single-stranded genome including the polynucleotide to a patient.2. A method of delivering an α-N-acetylglucosamidinase polynucleotide to the central nervous system comprising the step of systemically administering a rAAV9 comprising a single-stranded genome including the polynucleotide to a patient.3. The method of or wherein the polynucleotide is delivered to brain.4. The method of or wherein the polynucleotide is delivered to spinal cord.5. The method of or wherein the polynucleotide is delivered to a glial cell.6. The method of wherein the glial cell is an astrocyte.7. The method of or wherein the polynucleotide is delivered to a lower motor neuron.8. A method of delivering an α-N-acetylglucosamidinase polynucleotide to the peripheral nervous system comprising the step of administering a rAAV9 comprising a single-stranded genome including the polynucleotide to a patient.9. The ...

RILUZOLE PRODRUGS AND THEIR USE

Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process. 115-. (canceled)17. The method according to claim 16 , wherein the compound is selected from the group consisting of:(S)-2-amino-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)propanamide;(R)-2-amino-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)propanamide;(S)-2-amino-3-methyl-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)butanamide;(R)-2-amino-3-methyl-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)butanamide;(S)-2-amino-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)-3-phenylpropanamide;(R)-2-amino-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)-3-phenylpropanamide;(S)-2-amino-4-methyl-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)pentanamide;(R)-2-amino-4-methyl-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)pentanamide;(S)-2-amino-3-hydroxy-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)propanamide;(R)-2-amino-3-hydroxy-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)propanamide; and2-(2-aminoacetamido)-N-methyl-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)acetamide;or a pharmaceutically acceptable form thereof.18. ...

PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE

Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process. 131-. (canceled)33. The method of claim 32 , wherein the at least one compound is selected from the group consisting of:N-methyl-2-(methylamino)-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino) ethyl)acetamide;2-(ethylamino)-N-methyl-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino) ethyl)acetamide;2-(isopropylamino)-N-methyl-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino) ethyl)acetamide;2-(tert-butylamino)-N-methyl-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino) ethyl)acetamide;or a pharmaceutically acceptable form thereof.34. The method of claim 32 , wherein the at least one compound is administered in a composition further comprising at least one excipient.35. The method of claim 34 , wherein the at least one compound is administered in a composition further comprising an anticancer agent.36. The method of claim 35 , wherein the anticancer agent is selected from the group consisting of Vemurafenib claim 35 , Ipilimumab claim 35 , Masitinib claim 35 , Sorafenib claim 35 , Lenalidomide claim 35 , Oblimersen claim 35 , Trametinib claim 35 , Dabrafenib claim 35 , RO5185426 claim 35 , Veliparib claim 35 , Bosentan claim 35 , YM155 claim 35 , CNTO 95 claim 35 , CR011-vcMMAE claim 35 , CY503 claim 35 , Lenvatinib claim 35 , Avastin claim 35 , Tasidotin claim 35 , Ramucirumab claim 35 , IPI-504 claim 35 , Tasisulam claim 35 , KW2871 claim 35 , MPC-6827 claim 35 , RAF265 claim 35 , Dovitinib claim 35 , Everolimus claim 35 , MEK162 claim 35 , BKM120 claim 35 , ...

RILUZOLE PRODRUGS AND THEIR USE

Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process. 115-. (canceled)17. The method of claim 16 , wherein the at least one compound is selected from the group consisting of:(S)-2-amino-N-(2-(methyl (2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)propanamide;(R)-2-amino-N-(2-(methyl (2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)propanamide;(S)-2-amino-3-methyl-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)butanamide;(R)-2-amino-3-methyl-N-(2-(methyl (2-oxo-2-((6-(tri fluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)butanamide;(S)-2-amino-N-(2-(methyl (2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)-3-phenylpropanamide;(R)-2-amino-N-(2-(methyl (2-oxo-2-((6-(tri fluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)-3-phenylpropanamide;(S)-2-amino-4-methyl-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)pentanamide;(R)-2-amino-4-methyl-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)pentanamide;(S)-2-amino-3-hydroxy-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)propanamide;(R)-2-amino-3-hydroxy-N-(2-(methyl(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)amino)-2-oxoethyl)propanamide;2-(2-aminoacetamido)-N-methyl-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)acetamide;or a pharmaceutically acceptable form ...

NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE

Novel quinazolinones useful as inhibitors of tau oligomer formation, useful for the treatment of neurodegenerative diseases and related conditions are disclosed. The invention also relates to the pharmaceutically acceptable salts of said compounds, processes for the preparation of said compounds, intermediates used in the preparation of said compounds, and pharmaceutical compositions containing said compounds. The invention further relates to methods of use of said compounds, salts of said compounds, and said compositions in treating neurodegenerative diseases and related conditions. 6. A pharmaceutical composition for treating or preventing a disease or condition that involves the formation of tau oligomers comprising an effective amount of a compound according to and a pharmaceutically acceptable carrier.7. A method for treating or preventing a disease or condition that involve the formation of tau oligomers claim 1 , comprising administering to a patient in need of such treatment an effective amount of a compound according to and a pharmaceutically effective carrier.8. A method according to wherein the disease or condition is selected from Alzheimer's disease claim 7 , Amyotrophic lateral sclerosis/parkinsonism-dementia complex claim 7 , argyrophilic grain dementia claim 7 , corticobasal degeneration claim 7 , Creutzfeldt-Jakob disease claim 7 , dementia pugilistica/chronic traumatic encephalopathy claim 7 , diffuse neurofibrillary tangles with calcification claim 7 , Down's syndrome claim 7 , frontotemporal dementia with parkinsonism linked to chromosome 17 claim 7 , Gerstmann-Sträussler-Scheinker disease claim 7 , Hallervorden-Spatz disease claim 7 , myotonic dystrophy claim 7 , Niemann-Pick disease claim 7 , type C claim 7 , non-Guamanian motor neuron disease with neurofibrillary tangles claim 7 , Pick's disease claim 7 , postencephalitic parkinsonism claim 7 , prion protein cerebral amyloid angiopathy claim 7 , progressive subcortical gliosis claim 7 , ...

Communication method and communications device

This application provides a communication method and a communications device, so that both a location and a length of information carried in a data packet header are flexible and variable, the length does not need to be fixed, and the location does not need to be specified. Compared with a conventional protocol, the communication method has stronger flexibility and higher scalability. The method includes: obtaining, by a first device, a data packet, where the data packet includes a first packet header, the first packet header includes first indication information and a value of first packet header information, the first indication information is used to indicate a location of the value of the first packet header information, and the first packet header information is device identification information; and processing, by the first device, the data packet.

BINDING MOLECULE SPECIFICALLY FOR CD39 AND USE THEREOF

Provided is a binding molecule specifically for CD39 and the use thereof. Specifically, provided is an antibody that binds to CD39 and inhibits the activity of CD39 or an antigen binding part thereof, the use of the antibody or the antigen binding part thereof in the treatment of diseases, a nucleic acid molecule encoding the antibody or the antigen binding part thereof, an expression vector for expressing the antibody or the antigen binding part thereof, a host cell, and a preparation method. 190-. (canceled)91. An antibody or antigen-binding fragment thereof comprising a heavy chain variable region that comprises sequences of HCDR1 , HCDR2 , HCDR3; and a light chain variable region that comprises sequences of LCDR1 , LCDR2 , LCDR3 , wherein:(a) the HCDR1 comprises an amino acid sequence of SEQ ID NO: 5;(b) the HCDR2 comprises an amino acid sequence of SEQ ID NO: 6;(c) the HCDR3 comprises an amino acid sequence of SEQ ID NO: 7;(d) the LCDR1 comprises an amino acid sequence of SEQ ID NO: 10;(e) the LCDR2 comprises an amino acid sequence of SEQ ID NO: 59 or 11; and(f) the LCDR3 comprises an amino acid sequence of SEQ ID NO: 12.92. The antibody or antigen-binding fragment thereof of claim 91 , wherein:(i) the heavy chain variable region (VH) comprises an amino acid sequence with at least 85% identity to an amino acid sequence selected from a group consisting of SEQ ID NOs: 3, 60 and 72, and comprises HCDR1 comprising SEQ ID NO: 5, HCDR2 comprising SEQ ID NO: 6, and HCDR3 comprising SEQ ID NO: 7; and(ii) the light chain variable region (VL) comprises an amino acid sequence with at least 85% identity to an amino acid sequence selected from a group consisting of SEQ ID NOs: 8, 68 and 74, and comprises LCDR1 comprising SEQ ID NO: 10, LCDR2 comprising SEQ ID NO: 59 or 11, and LCDR3 comprising SEQ ID NO: 12.93. The antibody or antigen-binding fragment thereof of claim 91 , comprising:1) a heavy chain variable region (VH) that comprises an amino acid sequence with at least ...

NEGATIVE PRESSURE WOUND TREATMENT SYSTEM HAVING A BUFFER UNIT

Negative pressure wound therapy system with a buffering unit

METHOD FOR IDENTIFYING ORIGIN OF CHRYSANTHEMI FLOS

A method for identifying an origin of is provided, which belongs to the technical field of chemical analysis and detection, and comprises the following steps: mixing extract with aluminum ion solution, and gold nano-clusters (AuNCs) solution in a solvent, standing for reaction, detecting fluorescence intensity of , comparing the fluorescence intensity of to be detected with that of from a target origin, and determining whether they are from a same origin. According to the application, excited-state intramolecular proton transfer effect between 3-hydroxyflavone derivatives of and aluminum ions is utilized to enhance the fluorescence of -hydroxyflavone derivatives, where AuNCs combines aluminum ions to enhance aggregation-induced fluorescence, and reacts with flavonoids to quench their fluorescence; and visual characterization and traceability of quality are achieved by further comparing obvious rich fluorescence color changes before and after the reaction.

Actuator for negative pressure wound treatment system, has liquid limiter mounted in part of intake extension, and outlet tube connected to outlet connection of pump head, where part of extension is connected to fluid connection of shell

The actuator has a pump head (20) made of a biocompatible material and mounted in a shell (10). An intake extension (30) i.e. manifold, is respectively connected to an intake connection (21) of the pump head and a fluid connection (11) of the shell. A liquid limiter i.e. spiral tube (33), is mounted in a part of the intake extension, where the part of the intake extension is connected to the fluid connection of the shell. An outlet tube (40) is connected to an outlet connection (22) of the pump head.

Feedback control method for wound treating system to treat wound of user in e.g. hospital, by negative pressure to heal wound, involves sending detection results to determine whether operation mode is stopped

The method involves creating a negative pressure environment in an opening (511) of a dressing unit (50) of a wound treating system and a positive pressure environment in a collection bag of the system. A positive pressure detection procedure and a negative pressure detection procedure are conducted in the positive pressure environment and the negative pressure environment, respectively. Detection results are sent to determine whether an operation mode is stopped. An independent claim is also included for a system for treating a wound by negative pressure.

Switching circuit with independent dc power supply unit

Shell for mobile device and mobile device

The shell for a mobile device comprises one or more functional modules attached to the shell and a connector, the functional module being capable of being electrically connected to the mobile device via the connector and a first interface of the mobile device, for providing a corresponding function for the mobile device. Such a shell can not only provide protection function for the mobile device but also can enhance the performance of the mobile device, enrich the function of the mobile device and promote the user's experience in using the mobile device.

Negative pressure wound therapy system with a buffering unit

Backlight module and its optical lens

Parallelogram arm vehicle lift

A lift for transferring a user to and from a vehicle, the lift including a lift platform for receiving the user, the lift platform being arcuately movable between a first position and a second position; a vertical arm coupled to the lift platform, the vertical arm having a profile that is progressively convex along the entire length of the vertical arm; and a pair of parallel arms extending from the vertical arm, wherein each of the parallel arms is pivotally coupled to a bracket mounted to the vehicle; wherein the vertical arm has a generally U-shaped cross-section that forms a channel configured to receive at least a portion of the pair of parallel arms.

Feedback control method of negative pressure wound care system and negative pressure wound care system

Traditional chinese medicinal composition for the treatment of cardiovascular disease

Disc player

Actuator for low-pressure wound therapy system utilized for producing low pressure environment in wound and extracting sanies, has outlet tube connected with outlet port of pump head that is made of biocompatible material

The actuator (1) has a pump head made of a biocompatible material and attached in a housing (10). An inflow connection part is formed as a distribution pipe with a passage (31) and connected with the inflow port of the pump head and a fluid port (11) to the housing. A fluid limitation part is formed as a helical pipe and attached in a part of the inflow connection part, where the part of the inflow connection part is connected with the fluid port of the housing. An outlet tube (40) is connected with an outlet port of the pump head. The pump head is removably connected with an external motor.

Shielded enclosure and socket connector

揭示了一種屏蔽殼體及插座連接器。該插座連接器包括：一絕緣殼體，設有用於容納該插頭連接器的一容納腔；多個連接端子，安裝在該容納腔中；以及一屏蔽殼體，包覆在該絕緣殼體的外部。該屏蔽殼體包括：一第一立壁；與該第一立壁相對之一第二立壁；以及一接口壁，連接在該第一立壁及該第二立壁之間，該接口壁上形成有用於接收一個插頭連接器之一接收開口，該接收開口之一內側邊緣設有通過彎曲向內延伸的多個彈片，該多個彈片包括至少一個截面具有基本上一L形之一第一彈片。該第一彈片包括：一第一臂，從該接口壁的一外邊緣彎曲延伸，並抵靠在該接口壁的一個表面上；以及一第二臂，自該第一臂彎折延伸並朝向該接收開口內部延伸。可以增加該第一彈片對插入至該插座連接器中之該插頭連接器之一彈性接觸力，提高防電磁干擾性能。

Wounds treatment system, has control unit electrically connected to sensor and actuator, and actuator connected to cushioning unit and collector, where sensor is connected to cushioning unit that is connected between bandage and actuator

The system has a control unit (10) electrically connected to a sensor (20) and an actuator (30), where the actuator is connected to a cushioning unit (50) and a collector (40). The sensor is connected to the cushioning unit that is connected between a bandage (60) and the actuator. The cushioning unit includes a water absorbing layer (51) for draining water. Volume of the water absorbing layer is compressed when the volume of water is increased. The cushioning unit includes an air permeable layer (52) that is connected to the sensor.

Display screen with a graphical user interface

Method of manufacturing molded article with decorative pattern

A method of manufacturing a molded article with a decorative pattern thereon, includes the steps of: step ( 10 ), preparing a mold and a mask with a predetermined pattern thereon; step ( 11 ), mounting the mask in the mold; step ( 12 ), spraying ink or paint onto the mask to form a decorative pattern thereon; step ( 13 ), injecting a molten plastic into the mold to form a molded article body; and step ( 14 ), simultaneously transferring the decorative pattern from the mask onto the molded article body, and thus forming a molded article with a decorative pattern thereon.

Dihydroisoindolones as allosteric modulators of glucokinase

The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating glucokinase mediated disorders. More particularly, the compounds of the present invention are glucokinase modulators useful for treating disorders including, but not limited to, type II diabetes.

Fluid collector

Negative pressure wound therapy system with a buffering unit

A negative pressure wound therapy system has a buffering unit 50 connected between an actuator 30 and a wound dressing 60, a sensor 20 connected to the buffering unit 50, a controller 10 connected to the sensor 20 and an actuator 30, and a collector 40 connected to the actuator 30. The buffering unit 50 compensates for negative pressure loss in the wound and resists pressure rise in the wound during slight leakage, dampens the pressure variations from the actuator 30 which may be turned on and off according to the controller 40 and sensor 20, and keeps the actuator 30 from directly operating on the wound to reduce the pain of the patient while lowering the pressure in the wound. The buffering unit 50 may comprise a water-absorbing layer 51, an air-permeating layer 52 which stops liquid flowing into the sensor, and a mesh layer 53 to keep the buffer from collapsing (see figure 3). Under negative pressure the water-absorbing layer 51 compresses and water drains out into the collector. When the actuator is stopped, the water-absorbing layer expands.

Vacuum wound therapy system has actuator that is connected to buffer unit and collector, and sensor that is connected to buffer unit that is connected between wound dressing and actuator

The system has a controller, a sensor, an actuator, a collector (40), a wound dressing (60), and a buffer unit (50). The controller is electrically connected to the sensor and the actuator. The actuator is connected to the buffer unit and the collector. The sensor is connected to the buffer unit that is connected between wound dressing and the actuator.

Ventilative mattress structure

Method and system for obtaining flicker transfer coefficient in grid connection of photovoltaic power station

azetidinyl diamides as monoacylglycerol lipase inhibitors

Structure improvement for the airtight aluminum window

Electronic device having connecting mechanism

An electronic device includes a front cover, a rear cover engaging with the front cover, and a connecting mechanism fixed to the front cover. The front cover is secured to the rear cover to cooperatively define a receiving space for receiving a part of the connecting mechanism. The front cover includes a first panel defining two limiting members and a first sidewall extending from a rim of the first panel and defining two latching members. The rear cover includes a second panel defining two protrusions and a second sidewall extending from a rim of the second panel and defining two hook members. The protrusions correspond to the limiting members and are fixed thereto, and the hook members correspond to the latching members and engage therewith.

COLLECTOR FOR NEGATIVE PRESSURE WOUND TREATMENT SYSTEM AND COMBINATION OF SUCH COLLECTORS

L'invention porte sur un collecteur (1) pour système de traitement de plaie par pression négative, lequel collecteur a une unité de collecte ayant au moins un sac de collecte souple avec une unité perméable au gaz et un absorbeur de liquide (20), et relié à une unité pansement (51) par un ensemble de raccordement d'entrée (30) et à un ensemble capteur (53) par un ensemble de raccordement de détection. Avec le sac de collecte souple, le collecteur (1) occupe un volume moindre. Par l'unité perméable au gaz et l'absorbeur de liquide (20), le liquide et le gaz entrant dans le sac de collecte sont isolés rapidement. De plus, l'unité de collecte peut comprendre de multiples sacs de collecte (10) reliés en série pour former un passage d'écoulement continu, afin de réduire la fréquence de remplacement du collecteur, de telle sorte qu'un temps d'utilisation plus long est obtenu. A collector (1) for a negative pressure wound treatment system has a collector unit having at least a flexible collection bag with a gas permeable unit and a liquid absorber (20), and connected to a dressing unit (51) by an input connection assembly (30) and to a sensor assembly (53) by a detection connection assembly. With the flexible collection bag, the collector (1) occupies less volume. By the gas permeable unit and the liquid absorber (20), the liquid and the gas entering the collection bag are isolated quickly. In addition, the collection unit may include multiple collection bags (10) connected in series to form a continuous flow path, to reduce the frequency of collector replacement, such that an operating time longer is obtained.

Oxide semiconductor field effect transistor and forming method thereof

An oxide semiconductor field effect transistor (OSFET) includes a first insulating layer, a source, a drain, a U-shaped channel layer and a metal gate. The first insulating layer is disposed on a substrate. The source and the drain are disposed in the first insulating layer. The U-shaped channel layer is sandwiched by the source and the drain. The metal gate is disposed on the U-shaped channel layer, wherein the U-shaped channel layer includes at least an oxide semiconductor layer. The present invention also provides a method for forming said oxide semiconductor field effect transistor.

Method, device and system for determining message forwarding path

Embodiments of this application provide a packet forwarding path determining method, a device, and a system. The method includes: generating, by a first device, a first measurement packet, where the first measurement packet includes link resource indication information, and the link resource indication information in the first measurement packet is used to indicate each node on a forwarding path of the first measurement packet to perform local link resource measurement; and sending, by the first device, the first measurement packet to a next device on the forwarding path, where the first measurement packet includes local link resource information measured by the first device. Until the first measurement packet is forwarded to a third device by each node on the forwarding path of the first measurement packet, the third device receives the first measurement packets sent on different forwarding paths, and determines, based on the local link resource information in the first measurement packets received on the different forwarding paths, a path meeting the link resource indication information.

Display device

Disclosed is a display device comprising: a display panel; a driver chip; the driver chip is provided with a plurality of chip pins disposed spaced from each other, and the distance between at least two adjacent chip pins is different from the distance value between the other two chip pins; and a driving circuit board, the driving circuit board is provided with a plurality of circuit board contact points, and a circuit board contact point is connected to a chip pin correspondingly.

PREPARATION OF STABLE COLLOIDAL NANOCRYSTALLES USING ORGANIC DENDRONS

Improved LED structure

Heterocyclic compounds as factor ixa inhibitors

The present invention relates to novel heterocyclic compounds of Formulae I-III; as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder.

Method for generating a real time billing information in a packet switching based network and network element

The present invention proposes a method for generating a real time billing information in a packet switching based network and a network element for implementing Interworking between a circuit switching based network and a packet switching based network, wherein a call is set up between a user of said packet switching based network and a user of a circuit switching based network, and a billing server is informed of at least a billing rate and an interval of billing, said method for generating a real time billing information comprising: generating a first message with a first token indicating the billing rate upon receiving a first charge message containing said billing rate from said circuit switching based network and based on said first charge message, and the billing server is informed of said billing rate; once said call having been set up, generating a second messages with a second token indicating the interval of billing upon receiving a subsequent charge message containing said interval of billing and based on said subsequent charge message, and the billing server is informed of said interval of billing; and generating a real time billing information by said billing server.

ISOLATED ANTIBODIES OR ANTIGEN-BINDING FRAGMENT THEREOF, METHOD OF PREPARATION AND USES THEREOF, NUCLEOTIDE COMPOSITION, VECTOR, HOST CELL, PHARMACEUTICAL COMPOSITION, REAGENT FOR THE DETECTION OF LIF IN BIOLOGICAL SAMPLES, AND EXVIVO METHOD TO DETECT LIF IN BIOSPECIMEN

ANTICORPOS ISOLADOS OU FRAGMENTO DE LIGAÇÃO AO ANTÍGENO DOS MESMOS, USOS E MÉTODO DEPREPARAÇÃO DOS MESMOS, COMPOSIÇÃO NUCLEOTÍDICA, VETOR, CÉLULA HOSPEDEIRA, COMPOSIÇÃO FARMACÊUTICA, REAGENTE PARA DETECÇÃO DE LIF EM AMOSTRAS BIOLÓGICAS, E MÉTODO EX-VIVO PARA DETECTAR O LIF EM AMOSTRAS BIOLÓGICAS. É fornecida uma molécula de ligação específica para LIF e seu uso. Especificamente, é fornecido um anticorpo isolado ou um fragmento de ligação ao antígeno do mesmo que se liga ao LIF e inibe a atividade do LIF. Também são fornecidas as utilizações do anticorpo isolado ou do fragmento de ligação ao antígeno do mesmo no tratamento de doenças. ISOLATED ANTIBODIES OR ANTIGEN BINDING FRAGMENT THEREOF, USES AND METHOD OF PREPARATION THEREOF, NUCLEOTIDE COMPOSITION, VECTOR, HOST CELL, PHARMACEUTICAL COMPOSITION, REAGENT FOR DETECTION OF LIF IN BIOLOGICAL SAMPLES, AND EX-VIVO METHOD TO DETECT LIFBI IN SAMPLES . A specific binding molecule for LIF and its use is provided. Specifically, an isolated antibody or an antigen-binding fragment thereof that binds to LIF and inhibits the activity of LIF is provided. Also provided are uses of the isolated antibody or antigen-binding fragment thereof in the treatment of diseases.

Transforming asset operation video to augmented reality guidance model

A method, computer system, and a computer program product for AR guidance is provided. The present invention may include detecting a plurality of objects in a video recording associated with completing a task. The present invention may include generating a plurality of three-dimensional (3D) object models based on scanning a plurality of real objects in a task space. The present invention may include matching the detected plurality of objects in the video recording with the generated plurality of 3D object models representing the plurality of real objects in the task space. The present invention may include generating, based on the video recording, an augmented reality (AR) guidance model for completing the task, wherein the generated AR guidance model replaces the detected plurality of objects in the video recording with the generated plurality of 3D object models representing the plurality of real objects in the task space.

管件自動沖孔機

一種管件自動沖孔機，包括一沖壓裝置、一導料裝置及一送料裝置，該沖壓裝置設有至少一沖孔模組，該沖孔模組包含一下模、一內模及一上模，該下模具有貫通前後之一容置孔可供一管件插入，頂面具有貫通到該容置孔之一通孔，該內模設於該容置孔中且可供該管件套設於其上，且頂面具有一模槽延伸到前側邊呈開口狀，該上模可在該下模的上方昇降，且底部設有一沖頭可經過該通孔下移到該模槽中，以於該管件上沖壓出一穿孔，該導料裝置係設於該沖壓裝置的後側，且包含至少一導桿及一頂抵模組，該導桿的前端結合在該內模上可供該管件套設，該頂抵模組可將該導桿向上頂抵，以連動該內模位於該容置孔的中央而使兩者之間形成一間隙以便供該管件插入，該送料裝置包含可在該沖壓裝置前側移動之至少一夾具，該夾具可供夾住或釋放該管件的前端；藉由上述結構係可大幅提昇沖孔加工之效率及精密度，而且並可節省大量之人力成本。

Electronic device and infrared receiving device thereof

An exemplary infrared receiving device is adapted for mounting on a printed circuit board. The infrared receiving device includes an infrared receiver and a supporting seat configured to be mounted on the printed circuit board. The infrared receiver is attached to the supporting seat with the supporting seat supporting and protecting the infrared receiver. An electronic device includes a main body, a flip cover pivotably attached to the main body, and a display screen embedded in the flip cover. The main body includes a printed circuit board, an infrared receiver mounted on the printed circuit board, and a supporting seat mounted on the printed circuit board. The supporting seat holds the infrared receiver to support and protect the infrared receiver.

Planet gear type generator for electric motorcycle

面膜成型機的壓料裝置

一種面膜成型機的壓料裝置，包括一機台、一下壓架、一上壓架及兩昇降控制模組，該機台上設有一收集槽，該下壓架設於該機台上且位在該收集槽的正上方，該下壓架包含有複數下滾輪、一下驅動輪、繞設在該下滾輪與該下驅動輪上之一下皮帶及可驅動該下驅動輪之一下驅動馬達，該上壓架可昇降地設於該下壓架的正上方，使可供層疊之珍珠紙、纖維薄膜及不織布由該上、下壓架之間經過，該上壓架包含有複數上滾輪、一上驅動輪、繞設在該上滾輪與該上驅動輪上之一上皮帶及可驅動該上驅動輪之一上驅動馬達，兩昇降控制模組係分別設於該下壓架的前、後端部，可供分別驅動該上壓架的前、後端部昇降；藉由上述結構係具有可大幅降低產品的不良率、減少機器故障率及提昇運轉順暢度之功效。

Electronic device

An electronic device includes a main body, a lid, two hinge members, a reinforcing member and a covering structure. The main body has a top surface. The hinge members are disposed at two opposite ends of a side edge of the lid to rotatably connect the lid to the main body. The reinforcing member is disposed on the side edge and located between the two hinge members. The reinforcing member is inserted in the through hole to abut the main body. The covering structure is detachably mounted to the main body and partly covering the through hole.

Heat dissipation water-box structure improvement of liquid-cooling type heat dissipation system

Ticket knowledge graph enhancement

A computer-implemented method includes: extracting, by one or more processors, media data from an information technology ticket; extracting, by one or more processors, a plurality of data elements from the media data; and generating, by one or more processors, a ticket knowledge graph based on the plurality of data elements, wherein a node of the ticket knowledge graph represents a data element, and an edge between a first node and a second node in the ticket knowledge graph represents a correlation between a first data element represented by the first node and a second data element represented by the second node.

Key device for electronic apparatus

An exemplary key device includes a circuit board, a frame, a cap, a partition board and two protrusions. The circuit board has two contacts thereon. The cap is configured on the frame and includes a bottom surface facing the circuit board. The partition board extends down from the bottom surface and abutting against the circuit board. The two protrusions are at two opposite sides of the partition board. The two protrusions extend down from the bottom surface, and each includes a distal end adjacent and above a respective one of the contacts of the circuit board.

Protection apparatus of plural metal lamps

Bicycle wheel-attached type electricity generation and lighting composite device

Magnetic control loading apparatus having electricity generation potency and combined with adjusting driving machinery

Locking of screw part to lock against the locked plate

Structure of memory device and fabrication method thereof

The present invention relates to a structure of a memory device. The structure of a memory device includes a substrate, including a bottom electrode layer formed therein. A buffer layer is disposed on the substrate, in contact with the bottom electrode layer. A resistive layer surrounds a whole sidewall of the buffer layer, and extends upward vertically from the substrate. A mask layer is disposed on the buffer layer and the resistive layer. A noble metal layer is over the substrate, and fully covers the resistive layer and the mask layer. A top electrode layer is disposed on the noble metal layer.

Reproduction client application issue based on layered data replay

An approach for assisting software developers to fill the data gap and reproducing client application issue using reported reproducing steps is disclosed. The approach involves constructing service request/response sequence (from the developer's side based on the limited data) from customer's reproducing steps and developer's running inspection result and perform UI-service mapping, redirecting service call to data simulator which replay the service request and response, and adjusting service response with multiple data sources and policies. Lastly, the approach can transform the issue to an automatic test script with the service response in a mockup function (e.g., can be used to extend test data and enhance test cases).

Transforming asset operation video to augmented reality guidance model

A method, computer system, and a computer program product for AR guidance is provided. The present invention may include detecting a plurality of objects in a video recording associated with completing a task. The present invention may include generating a plurality of three-dimensional (3D) object models based on scanning a plurality of real objects in a task space. The present invention may include matching the detected plurality of objects in the video recording with the generated plurality of 3D object models representing the plurality of real objects in the task space. The present invention may include generating, based on the video recording, an augmented reality (AR) guidance model for completing the task, wherein the generated AR guidance model replaces the detected plurality of objects in the video recording with the generated plurality of 3D object models representing the plurality of real objects in the task space.

Transforming asset operation video to augmented reality guidance model

A method, computer system, and a computer program product for AR guidance is provided. The present invention may include detecting a plurality of objects in a video recording associated with completing a task. The present invention may include generating a plurality of three-dimensional (3D) object models based on scanning a plurality of real objects in a task space. The present invention may include matching the detected plurality of objects in the video recording with the generated plurality of 3D object models representing the plurality of real objects in the task space. The present invention may include generating, based on the video recording, an augmented reality (AR) guidance model for completing the task, wherein the generated AR guidance model replaces the detected plurality of objects in the video recording with the generated plurality of 3D object models representing the plurality of real objects in the task space.

Electronic device with mechanism for securing connector thereof

An electronic device includes a circuit board, a connector fixed on the circuit board, and a heat sink mounted on the circuit board. The heat sink includes a securing portion. The securing portion defines a first cutout, a second cutout, and an arm located between the first and second cutouts. The arm resiliently urges the connector against the circuit board so as to firmly hold the connector between the heat sink and the circuit board.

Electronic equipment and IR receiver

Electronic device

An electronic device includes a main body, a lid, two hinge members, a reinforcing member and a covering structure. The main body has a top surface. The hinge members are disposed at two opposite ends of a side edge of the lid to rotatably connect the lid to the main body. The reinforcing member is disposed on the side edge and located between the two hinge members. The reinforcing member is inserted in the through hole to abut the main body. The covering structure is detachably mounted to the main body and partly covering the through hole.

Slide button, switching assembly, and electronic device using the same

A slide button, used for activating a mode of an electronic device by operating a toggle switch on a circuit board of the electronic device, includes an operating member, an activating member, and a positioning member. The operating member defines a first surface used for applying a force therein and a second surface opposite to the first surface. The activating member includes two tail fins and a positioning member respectively extending from the second surface. The tail fin defines an opening. The toggle switch is received in the opening. The connecting board is received in the opening and used for enhancing the strength of the two tail fins. The positioning member is connected to the two tail fins and spaced apart from the operating member. The positioning member and the operating member together secure the slide button to the electronic device.

Touch panel detection apparatus